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General Introduction 
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Lymphoid tumors are known to be common hematopoietic tumor in dogs (Dobson 
et al., 2002). Among canine lymphoid tumors, lymphoma is most common and 
comprises 83% of all hematopoietic neoplasms (Vail and Young, 2007). Canine 
lymphoma has been considered to be a clinically heterogenous disease, because the 
prognosis of dogs with lymphoma varied among patients. Therefore, canine lymphoma 
is divided into a number of subtypes based on its anatomic form, immunophenotype, 
and cytological or histological characteristics (Marconato et al., 2013). Among these 
subtypes, multicentric B-cell high-grade lymphoma (diffuse large B-cell lymphoma) is 
the most common subtype in dogs (Vezzali et al., 2010). 
As a treatment for dogs with lymphoma, combination chemotherapy is generally 
selected, and various chemotherapeutic protocols have been reported (Marconato et al., 
2013). Among these protocols, CHOP-based protocol using cyclophosphamide, 
doxorubicin and vincrisitine is a representative protocol as treatment for canine 
lymphoma (Garrett et al., 2002). Such chemotherapy protocol yields complete responses 
in over 80% of dogs with lymphoma (Marconato et al., 2013). However, the duration of 
this remission is generally as short as 6 - 11 months, and post-remission chemotherapy 
(rescue protocol) is usually not effective for dogs with lymphoma after relapse although 
various rescue protocols have been proposed (Vail and Young, 2007). The progression 
free survival time when these rescue protocols were conducted was reported to be 61- 
70 days (Alvarez et al., 2006; Rassnick et al., 2002; Saba et al., 2009), and the treatment 
outcome for dogs with high-grade lymphoma is not satisfactory. 
The most common cause of the failure in the treatment for canine lymphoma is the 
acquisition of the multidrug resistance (MDR) by tumor cells (Bergman, 2003). A 
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number of factors associated with MDR have been studied in human and veterinary 
medicines (Bergman, 2003; Lage, 2008). Among these factors, a number of molecules 
have been reported to contribute to acquire the MDR phenotype in humans 
(Gimenez-Bonafe et al., 2009; Harris and Hochhauser, 1992; Kaina and Christmann, 
2002). Such molecules are known to mediate reduced drug accumulation, decreased 
apoptosis, increased detoxification and increased DNA repair. Based on these 
observations, the acquisition of MDR phenotype is thought to be multifactorial. 
Of the factors associated with MDR, the overexpression of drug efflux pumps such 
as ATP-binding cassette (ABC) transporter family is one of the mechanisms that have 
been most extensively studied in both human and veterinary medicines (Bergman, 2003; 
Lage, 2008). The overexpression of drug efflux pumps leads to reduce the intracellular 
drug concentrations and confers MDR phenotype to tumor cells. Among ABC 
transporter family, P-glycoprotein (P-gp, the product of ABCB1 gene, formerly called 
MDR1 gene), multidrug resistance-associated protein 1 (MRP1) (the product of ABCC1 
gene) and breast cancer-resistant protein (BCRP) (the product of ABCG2 gene) are 
representative ABC transporters associated with acquisition of MDR in human tumor 
cells (Modok et al., 2006). Besides ABC transporters, overexpression of lung 
resistance-associated protein (LRP) is also reported to be associated with MDR 
phenotype in human tumor cells (Izquierdo et al., 1996). LRP has different function 
from P-gp, MRP1 or BCRP and redistributes drugs from the nucleus to the cytoplasm 
because it is expressed on nuclear membrane (Gromicho et al., 2011).  
In veterinary medicine, expression of P-gp was reported to be enhanced in cells of 
relapsed and chemotherapy-resistant dogs with lymphoma (Bergman et al., 1996; Lee et 
al., 1996; Moore et al., 1995), and expression of P-gp has been detected in a 
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chemotherapeutic agent-resistant canine lymphoma cell line (Uozurmi et al., 2005). 
As mechanisms that induce the overexpression of genes coding drug efflux pumps, 
gene amplification, increase of amount or translocation of transcriptional factors, 
change in epigenetic regulation, and modulation of intracellular signaling have been 
suggested especially in ABCB1 gene in human tumor cells (Chen and Sikic, 2012). 
However, the mechanisms that induce the overexpression of drug transporters have not 
been well understood. In addition, no study on the mechanisms of expression regulation 
of genes coding drug efflux pumps has been conducted in veterinary medicine. 
Based on the results of studies that indicated the association of the overexpressions 
of drug transporters with MDR phenotype in tumor cells, it has been attempted to 
inhibit the function of drug transporters overexpressed in tumor cells. Mainly, two 
methodologies to overcome the MDR induced by overexpressions of drug efflux pumps 
have been proposed in human medicine; inhibition of drug transporters function such as 
competitive inhibition (Shukla et al., 2012) and reduction of the expression of drug 
transporters (Abbasi et al., 2013). However, both methodologies have not been 
successfully applied into clinical practice because of the adverse events after application 
of these strategies. 
Although expression of P-gp or other drug efflux pumps has been demonstrated in 
a variety of MDR tumors in both humans and dogs, these expressions are not always 
linked to MDR in vivo and the inhibition of drug efflux pumps cannot always 
reestablish the sensitivity for drugs (Leonard et al., 2003). This might be due to the 
phenomena that acquisition of MDR is multifactorial, although the overexpression of 
drug transporters is one of the most important MDR factors. Therefore, other MDR 
factors than drug efflux pumps are needed to be identified. 
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From these backgrounds, I conducted a series of studies to elucidate the 
mechanisms of acquisition of MDR in canine lymphoma. In chapter 1, I conducted 
experiments focusing on 10 molecules known to be associated with MDR in human 
medicine, and the results indicated the overexpression of ABCB1 gene in a proportion of 
dogs with lymphoma showing MDR. Therefore, I performed a series of studies to 
identify molecular mechanisms to induce the overexpression of ABCB1 gene and to 
explore strategies to modulate the gene expression in chapters 2 to 4. Finally, for further 
development of these studies, comprehensive analysis of the gene expression profiles 
associated with MDR in canine lymphoma patients were conducted in chapter 5. 
In chapter 1, I compared the mRNA expressions of 10 different factors that have 
been known to be associated with MDR in canine tumor cells between drug-sensitive 
and drug resistant patients. Based on the results obtained in chapter 1, epigenetic 
regulation of ABCB1 gene expression through DNA methylation and histone H3 
acetylation was explored in canine lymphoid tumor cell lines in chapter 2. In addition, 
analysis of DNA methylation statuses was also performed in primary tumor cells 
derived from dogs with multicentric B-cell high-grade lymphoma. In chapter 3, the 
regulation of ABCB1 and LRP gene expressions through the intracellular signaling, 
MAPK/ERK pathway, was examined. Based on the results obtained from chapter 3, 
antitumor effect and modulation of ABCB1 gene expression through modulation of 
intracellular signals by perifosine, an Akt inhibitor, were examined in canine lymphoid 
tumor cell lines in chapter 4. Finally, I investigated MDR mechanisms that have not 
been examined in canine tumor cells by comprehensive analysis of gene expression 
proflies using canine B-cell high-grade multicentric lymphoma patient samples collcted 
at drug-sensitive and MDR phases in chapter 5. 
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Chapter 1 
 
Quantitative analysis of mRNA for 10 different  
drug resistance factors in dogs with lymphoma 
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Abstract 
 
Expression levels of ABCB1, ABCC1, Lung resistance-associated protein (LRP), 
ABCG2, p53, p21
waf1
, Bcl-2, CD40L, glutathione S-transferase alpha (GSTα), and 
O
6
-methylguanine-DNA-methyltransferase (MGMT) genes, and mutation of p53 gene 
were examined in 23 dogs with multicentric high-grade lymphoma to explore their 
association with drug resistance of the tumor cells. Dogs were divided into 
chemotherapy-sensitive (n=13) and -resistant (n=10) groups according to the response 
to a 6-month modified version of the University of Wisconsin (UW)-Madison 
chemotherapy protocol (UW-25), and expression levels of these factors and frequency 
of p53 gene mutation were compared between the two groups. No significant difference 
was observed in expression levels of each factor between the groups. However, elevated 
expression level of ABCB1 gene was observed in 3 dogs in the chemotherapy-resistant 
group. No significant difference was observed in the frequency of p53 mutation 
between the two groups. A possible association of ABCB1 with resistance to UW-25 
was indicated, but no uniform mechanism associated with drug resistance could be 
identified in dogs with lymphoma. 
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Introduction 
 
Drug resistance is the most common cause of failure in chemotherapy for dogs with 
lymphoma. A number of factors associated with drug resistance have been studied in 
human and veterinary medicines (Bergman, 2003; Lage, 2008). Among these factors, a 
number of molecules have been reported to contribute to the mechanisms of 
chemotherapy resistance of tumors in humans (Gimenez-Bonafe et al., 2009; Harris and 
Hochhauser, 1992; Kaina and Christmann, 2002). 
Various studies have been conducted to elucidate drug resistance in various human 
tumors. Over-expressions of transport proteins including P-glycoprotein (P-gp) (the 
product of ABCB1, formerly called MDR1 gene (O'Connor, 2007)), multidrug 
resistance-associated protein 1 (MRP1) (the product of ABCC1 gene (O'Connor, 2007)), 
lung resistance-associated protein (LRP) (Izquierdo et al., 1996), and breast 
cancer-resistant protein (BCRP) (the product of ABCG2 gene (Burger et al., 2003)) are 
known to be the major mechanism of reduced intracellular drug accumulation. 
Mechanisms of decreased apoptosis include aberrations of p53 gene and 
over-expression of Bcl-2 (Buchholz et al., 2003; Khor et al., 2007; Kupryjanczyk et al., 
2003; Nagamatsu et al., 2008). Wild-type P53 has many functions, such as induction of 
a transient (cell cycle arrest) or permanent (senescence) blockage of cell proliferation 
and the activation of cell death pathways in response to genotoxic stress (apoptosis). In 
particular, in the regulation of the cell cycle, wild-type P53 promotes the expression of 
P21
WAF1
 (Kim et al., 2009). CD40L is expressed on the T lymphocytes and is known to 
promote the survival of the B-cell lymphoma cells through activation of CD40 on 
12 
 
cancer cells (Voorzanger-Rousselot and Blay, 2004). Meanwhile, one recent study 
(Voorzanger-Rousselot et al., 1998) reported coexpression of CD40 and CD40L on B 
lymphoma cells, suggesting its autocrine anti-apoptotic role. Increased detoxification is 
also considered to mediate drug resistance. Glutathione S-transferase (GST) acts to 
induce detoxification of cytotoxic drugs (Moscow and Dixon, 1993). DNA repair 
pathways are also known to be involved in the development of drug resistance. 
O
6
-alkylguanine DNA alkyltransferase, which is encoded by O
6
-methylguanine DNA 
methyltransferase (MGMT) gene, has been reported to provide resistance to treatment 
with alkylating agents (Brent et al., 1985; Gerson, 2004; Schold et al., 1989).  
In veterinary medicine, expression of P-gp was reported to be enhanced in tumor 
cells of dogs with relapsed or chemotherapy-resistant lymphoma (Bergman et al., 1996; 
Lee et al., 1996; Moore et al., 1995), and expression of P-gp was detected in a 
chemotherapeutic agent-resistant canine lymphoma cell line (Uozurmi et al., 2005). 
However, association of ABCC1, LRP, ABCG2, p53, Bcl-2, CD40L, GST and MGMT 
gene with drug resistance has not been reported in canine lymphoma. The objective of 
the study in chapter 1 was to reveal the correlations between these drug resistance 
factors and multidrug resistance in dogs with lymphoma by measuring expressions of 
ABCB1, ABCC1, LRP, ABCG2, p53, p21
waf1
, Bcl-2, CD40L, GSTα, and MGMT gene 
using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) system and 
detecting p53 gene mutations. 
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Materials and methods 
 
Animals 
Twenty-three dogs with age ranging from 2.7 to 11.8 years were examined. Of the 
23 dogs, 13 were females (9 spayed) and 10 were males (3 castrated). Breeds of these 
dogs were Golden Retrievers (n=5), Welsh Corgi Pembroke (n=2), Shih Tzu (n=2), 
Miniature Schnauzer (n=2), Border Collie (n=2), Miniature Dachshund (n=2), Shiba Inu 
(n=1), Polish Lowland Sheepdog (n=1), Pug (n=1), Australian Kelpie (n=1), French 
Bulldog (n=1), Scottish Terrier (n=1), Shetland Sheepdog (n=1), and Bernese Mountain 
Dog (n=1). Twenty-one of the 23 dogs had been referred to the Veterinary Medical 
Center of the University of Tokyo. The remaining 2 dogs had been referred to private 
veterinary hospitals and the samples were sent to our laboratory. All dogs were 
diagnosed with multicentric lymphoma based on cytological examinations of enlarged 
lymph nodes. According to the cytological examinations, the 23 dogs were diagnosed as 
high-grade lymphoma based on the updated Kiel classification (Fournel-Fleury et al., 
1997). Lymphoma cell samples from all 23 dogs were shown to be clonally expanded 
B-lymphoid cells by PCR amplification test for the antigen receptor gene 
rearrangements as described previously (Burnett et al., 2003).  
   Evaluation of response to treatment: Veterinarians measured the size of the lymph 
nodes with calipers at each admission, and response to treatment was evaluated based 
on the new Response Evaluation Criteria in Solid Tumors (RECIST) (Eisenhauer et al., 
2009). In the evaluation of response to treatment, complete remission (CR) and partial 
remission (PR) were regarded as indicating chemotherapy-sensitive status, and stable 
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disease (SD) and progressive disease (PD) were regarded indicating as 
chemotherapy-resistant status. 
 
Treatment 
A cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, plus 
prednisolone (CHOP)-based chemotherapy, 6-month modified version of the University 
of Wisconsin (UW) - Madison chemotherapy protocol (UW-25) (Garrett et al., 2002), 
was used as a standard multidrug combination chemotherapy protocol. However, 
administration of L-asparaginase (L-asp) was omitted in most of the cases, because 
L-asp has been reported to have no influence on the efficacy of the UW-25 protocol 
(MacDonald et al., 2005). One dog of chemotherapy-resistant group received L-asp at 
week 1 of UW-25 protocol. All dogs that were enrolled in this study had not received 
any chemotherapeutic agent before the application of UW-25 protocol; however, three 
dogs in chemotherapy-sensitive group and two dogs in chemotherapy–resistant group 
had received corticosteroids for 1 day - 1 month before chemotherapy. 
 
Definition of patient groups 
Chemotherapy-sensitive dogs were defined as those achieving CR or PR by week 5 
of the UW-25 protocol. Tumor cell samples were collected just prior to the 
chemotherapy at the initial consultation. Chemotherapy-resistant dogs were defined as 
those that had underwent a relapse after achieving remission by UW-25 protocol and did 
not respond to all of the three chemotherapeutic agents used for UW-25, 
cyclophosphamide, doxorubicin, and vincristine. The tumor cell samples of the 
chemotherapy-resistant group were collected after confirming the non-responsiveness to 
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these three drugs in conjunction with prednisolone after the relapse. 
 
RNA extraction and reverse transcription 
Total RNA was extracted from samples obtained by fine-needle aspiration (FNA) of 
neoplastic lymph nodes using RNAqueous (Ambion, Austin, TX) and treatment with 
DNase I (Invitrogen, Carlsbad, CA). To synthesize cDNA, total RNA was reverse 
transcribed using a PrimeScript
TM
 RT reagent Kit (Perfect Real Time) (Takara Bio, 
Shiga, Japan). 
 
Real-time PCR 
Oligonucleotides complementary to the sequences of ABCB1, ABCC1, LRP, ABCG2, 
p53, p21
waf1
, Bcl-2, CD40L, GSTα and MGMT genes were designed using Primer3 
software (http://frodo.wi.mit.edu/primer3/input.htm). The mRNA sequences of factors 
other than the LRP gene were identified at Genbank, and that of LRP gene was 
identified at Ensembl (transcript ID ENSCAFT00000026871, partial).  
For normalization of the amount of cDNA sample, selection of the internal reference 
was carried out prior to the setting of quantitative analysis of the factors possibly related 
to the drug resistance. Candidates for an internal reference included TATA box binding 
protein (TBP), ribosomal protein L13a (RPL13A) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) genes (Peters et al., 2007). Expressions of these three genes 
were quantified, and accuracies as internal control were analyzed using geNorm v 3.5 
software  (http://medgen.ugent.be/~jvdesomp/genorm) (Schlotter et al., 2009). From 
the result of this analysis, TBP gene was selected for use as an internal reference. The 
same primer pair for TBP gene was used as in a previous report (Peters et al., 2007). 
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Sequences of the primers are listed in Table 1-1. Amplification of products was 
confirmed by electrophoresis. Real-time PCR for quantification of mRNA for ABCB1, 
ABCC1, LRP, ABCG2, p53, p21
waf1
, Bcl-2, CD40L, GSTα and MGMT genes was 
performed using a Thermal Cycler Dice Real Time System TP800 (Takara Bio). 
Twenty-five microliters of the PCR mixture contained 12.5 l of Master Mix (SYBR® 
Premix Ex Taq
TM
 (Perfect Real Time)) (Takara Bio), 200 nM of sense and reverse 
primers, and 50 ng of cDNA. The cDNA samples were subjected to activation at 95 C 
for 10 s, then 40 cycles of denaturation at 95 C for 5 s, and annealing/extension at 62 
C for 30 s. After 40 cycles, samples were run using the dissociation protocol to verify 
the occurrence of a single melting peak. In this assay, 6-carboxyfluorescein (FAM) 
binds to double-stranded DNA, and increased fluorescence is detected. The results are 
expressed as the threshold cycle (CT), that is, the cycle number at which increasing 
reporter fluorescence crossed a fixed threshold baseline.  
For each factor and TBP gene, an assay-specific standard curve with serial (10) 
dilution of tumor cell cDNA from a dog with multicentric high-grade lymphoma was 
prepared. In these standard curves, the relative quantity of cDNA for each factor and 
TBP gene which was included in 50 ng of this cDNA sample was defined 10
5
. These 
standard curves were examined in triplicate. The relative quantity of each factor and 
TBP gene in lymphoma cells of dogs included in this study was calculated by plotting 
CT in the prepared standard curve. To normalize the amount of cDNA sample, the ratio 
of the relative quantity of cDNA for each factor to that of TBP gene was adopted. All 
samples were examined in duplicate. 
 
Examination of p53 gene mutation 
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The sequence of cDNA for p53 gene was divided into three fragments (fragments A, 
B and C) for PCR amplification and sequence analysis and three pairs of primers were 
selected for each of fragment A (nucleotides 2 to 479), fragment B (nucleotides 341 to 
778), and fragment C (735 to 1,178), as described previously (Setoguchi et al., 2001). 
Primer sequences are listed in Table 1-2. The cDNA of p53 gene for each dog was 
amplified by PCR using TaKaRa Ex Taq
®
 (Takara Bio) and primer pairs for each 
fragment. The cDNA samples were subjected to 30 cycles of denaturation at 98 C for 
10 s, annealing at 55 C for 30 s and extension at 72 C for 1 min. The sequence of each 
fragment was analyzed directly from PCR products using a BigDye terminator v3.1/1.1 
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and Applied Biosystems 
3130xl genetic analyzer (Applied Biosystems). When the sequence of cDNA of p53 
gene fragment could not be analyzed directly, PCR products were inserted into a T/A 
cloning vector (pGEM – T Easy) (Promega Corporation, Leiden, The Netherlands), and 
subjected to sequence analysis. Ten clones from each cDNA sample were sequenced. To 
confirm aberration in function of P53 protein, relative quantities of p21
waf1
 cDNA were 
compared between dogs that had mutations in p53 gene and those without mutations. 
 
Statistical analysis 
Relative quantities of cDNA for each factor were compared between 
chemotherapy-sensitive and -resistant groups using the Wilcoxon rank-sum test. 
Relative quantities of p21
waf1
 cDNA between dogs with p53 gene mutation and dogs 
with wild-type p53 gene were compared using the same test. In addition, frequency of 
mutation in the p53 gene was also compared between chemotherapy-sensitive and 
-resistant groups using Fisher’s exact probability test. Value of P < 0.05 was considered 
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statistically significant. Statistical testing was performed using JMP version 5.0.1 (SAS 
Institute, Cary, NC). 
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Results 
 
PCR amplification using primer pairs and accuracy of the real-time RT-PCR system 
PCR amplification of cDNA samples with each primer pair yielded distinct bands of 
predicted size (Fig. 1-1). Analysis of dissociation curves revealed a single melting peak 
for each factor, indicating the specificity of primer pairs (data not shown). The accuracy 
of the real-time RT-PCR system developed in this study was examined using cDNAs 
that were used to make standard curves in triplicate. According to these examinations, 
differences  0.3 in CT were regarded as intra-assay error. Ranges of r values and slopes 
of the standard curves for each drug resistance factors were 0.991 ~ 0.999 and -3.244 ~ 
-3.85, respectively. The variation in duplicate analyses was also  0.3 in CT, and the 
results were reasonably repeatable and precise. 
 
Comparison of expression levels of factors between groups 
Of the 23 dogs included in this study, 13 were chemotherapy-sensitive and 10 were 
chemotherapy-resistant. No significant difference was observed in expression level of 
any factor between chemotherapy-sensitive and -resistant groups (Table 1-3 and Fig. 
1-2). However, elevated expression of ABCB1 was observed in 3 dogs in the 
chemotherapy-resistant group, with increases of 19- to 33-fold greater than the median 
relative quantity in the sensitive group. 
 
Mutation in p53 gene 
In 6 (26.1%) of 23 dogs, mutations in p53 gene were observed. Of these 6 dogs, 2 
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were chemotherapy-sensitive, and 4 were chemotherapy-resistant. Five dogs showed a 
missense point mutation in p53 gene (Cys
163
 to Tyr, Arg
145
 to Cys, Ser
114 
to Pro, Arg
261
 
to Cys, and Arg
237
 to Trp, respectively), and 1 dog showed a 1-base deletion (G, nt 453) 
resulting in introduction of a stop codon at codon 156 (Table 1-4). No significant 
difference was observed in the frequency of p53 gene mutation between 
chemotherapy-sensitive and -resistance groups. The relative quantity of p21
waf1
 cDNA 
was significantly lower in dogs with p53 gene mutation than in those with wild-type 
p53 gene (P=0.02) (Fig. 1-3).  
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Discussion 
 
   In this study, no significant difference was observed between the 
chemotherapy-sensitive and –resistant groups in relative quantities of mRNA for 
various genes known to have possible associations with drug resistance. Reasons for 
this result may include the fact that the relative quantities of cDNA for each factor 
varied among dogs. However, 3 dogs in the chemotherapy-resistant group showed 
elevated expression of ABCB1. Although the ABCB1 expression was conceivably 
associated with the resistance to UW-25, a possibility that the ABCB1 expression was a 
result of exposure to P-gp substrates such as doxorubicin and vincristine could not be 
excluded. Similar results were obtained in a previous report on canine lymphoma 
(Moore et al., 1995), in which expression of P-gp protein was detected in 1 of 30 
lymphoma tissues prior to chemotherapy, meanwhile it was detected in 3 of 8 
lymphoma tissues at the chemotherapy resistance phase. In addition, two other studies 
on canine lymphoma (Bergman et al., 1996; Lee et al., 1996) showed that the rates of 
dogs with P-gp expression was higher after relapse than before treatment, and the dogs 
with P-gp expression prior to chemotherapy had low remission rate and short survival 
time. From the results in the present study in conjunction with those in previous reports, 
P-gp could conceivably be associated with resistance to chemotherapy in a subset of 
dogs with lymphoma. As shown in the study by Moore et al. (Moore et al., 1995), less 
than half of chemotherapy-resistance canine lymphoma cases showed positive results 
for P-gp expression in the tumor tissues. In the present study, 10 kinds of the associated 
molecules were examined for elucidation of the molecular mechanism that confers drug 
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resistance on canine lymphoma cells. However, any consistent change associated with 
the drug resistance could not be found; therefore, further effort is needed to clarify the 
drug resistance mechanism in canine lymphoma. 
In this study, the quantity of ABCB1 mRNA was measured by real-time RT-PCR, 
whereas in the previous three studies (Bergman et al., 1996; Lee et al., 1996; Moore et 
al., 1995) P-gp expression was examined at the protein level. Kourti et al. (Kourti et al., 
2007) reported that high ABCB1 mRNA expression was correlated with the worse 
prognosis in childhood acute lymphoblastic leukemia. However, there is also a report 
which indicated that ABCB1 gene mRNA level in the lymphoma tissues did not 
correlate with the clinical response to doxorubicin in dogs (Steingold et al., 1998). 
Studies on the expression analysis in protein level are warranted with respect to a 
number of molecules possibly associated with drug resistance; however, it is 
problematic that antibodies cross-reacting with proteins of these canine counterparts are 
not easily available at a moment. 
Although frequency of p53 gene mutation was not significantly different between 
chemotherapy-sensitive and -resistant groups, relative quantity of p21
waf1
 cDNA was 
significantly lower in dogs with p53 gene mutations than in those with wild-type p53 
gene (P=0.02). This result indicates a loss of function of the product from the mutated 
p53 gene compared to wild-type P53. However, the correlation between p53 gene 
mutation and drug resistance in dogs with lymphoma could not be identified and 
expression levels of p21
waf1
 were not significantly different between the 
chemotherapy-sensitive and –resistant groups. The p53 gene mutations found in the 2 
chemotherapy-sensitive lymphoma patients prior to chemotherapy were considered to 
be generated through the molecular events to develop lymphoma. The mutations 
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detected in 4 dogs in the chemotherapy-resistant group could be a result of exposure to 
chemotherapeutic agents or acquisition of drug resistance as well as the 
lymphomagenesis. 
   In the present study, the samples from chemotherapy-sensitive patients were 
obtained prior to chemotherapy, whereas those from chemotherapy-resistant patients 
were collected at the relapse when the patients had been already received 
chemotherapeutic agents. Therefore, the differences in the gene expression profile 
between the chemotherapy-sensitive and -resistant groups might be a result of the 
acquisition of chemotherapy-resistance or the exposure to chemotherapeutic agents. In a 
pretreatment phase, only a small proportion of dogs with lymphoma show resistance to 
chemotherapy. When it is possible, comparison of gene expression profile prior to 
chemotherapy between the chemotherapy-sensitive and –resistant groups would deny 
the influence of exposure to the drugs. In addition, the change of gene expression profile 
during the acquisition of drug resistance should be evaluated in individual dogs, because 
the variation of expression levels of each factor among dogs was large in this study. 
Considering these limitation in the present study, further effort is needed to accurately 
understand the molecular mechanism of drug resistance in dogs with lymphoma. 
   In conclusion, although a possible association of P-gp with chemotherapy resistance 
in canine lymphoma was indicated, no single factor could comprehensively explain 
chemotherapy-resistant in dogs with lymphoma. However, like P-gp in this study, 
chemotherapy resistance in individual cases might be associated with some factors. 
Besides the factors examined in this study, epigenetic changes in tumor cells (Lee et al., 
2008) and cancer stem cell hypothesis have recently come into greater focus as 
mechanisms associated with drug resistance (Hirschmann-Jax et al., 2004). Further 
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studies employing such strategies would be warranted to elucidate the mechanisms of 
chemotherapy resistance in dogs with lymphoma. 
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Table 1-4. 
Mutations in p53 gene detected in dogs with lymphoma. 
 
Dog Mutations 
4 TGC to TAC, Cys163 to Tyr 
8 CGC to TGC, Arg145 to Cys 
16 G (nt 453) deletion, stop codon156 
17 TCC to CCC, Ser114 to Pro 
18 CGC to TGC, Arg261 to Cys 
21 CGG to TGG, Arg237 to Trp 
29 
 
 
 
 
Fig. 1-1. Amplification of products using the primer pairs for real-time RT-PCR. RT-PCR using 
primer pairs for ABCB1 (lane 1), ABCC1 (lane 2), LRP (lane 3), ABCG2 (lane 4), p53 (lane 5), 
p21
waf1
 (lane 6), Bcl-2 (lane 7), CD40L (lane 8), GSTα (lane 9), MGMT (lane 10) and TBP (lane 
11) genes gave distinct bands of predicted size. M; size marker. 
 
M M 
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Fig.1-3. Comparison of relative quantities of cDNA for p21
waf1 
between dogs with p53 gene 
mutation and dogs with wild-type p53 gene. In the mutated p53 group, the relative quantity of 
cDNA of p21
waf1
 was significantly lower than that of the wild-type p53 gene group (P=0.02). 
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Chapter 2 
 
Epigenetic regulation of ABCB1 gene expression  
in canine lymphoid tumor cells 
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Chapter 2-1 
 
Epigenetic regulation of the ABCB1 gene 
 in drug-sensitive and drug-resistant lymphoid 
tumor cell lines obtained from canine patients 
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Abstract 
 
Multidrug resistance (MDR) is a major obstacle in the treatment of cancer. 
Overexpression of P-gp, encoded by the ABCB1 gene, is an important factor in 
determining the MDR phenotype of a tumor. Although recent studies have revealed the 
epigenetic transcriptional regulation of the human ABCB1 gene, such regulation of this 
gene has not been examined in dogs. The aim of this study was to evaluate differences 
in epigenetic regulation of the ABCB1 gene, between drug-sensitive and drug-resistant 
canine lymphoid tumor cell lines. In two drug-sensitive cell lines, GL-1 and CLBL-1, 
ABCB1 mRNA expression was significantly lower than in two drug-resistant cell lines, 
UL-1 and Ema, using real-time quantitative polymerase chain reaction (QPCR). 
Bisulphite sequencing and real-time methylation-specific PCR revealed that the CpG 
island present in the upstream region of exon 2 was hypermethylated in GL-1 and 
CLBL-1, but hypomethylated in UL-1 and Ema. Chromatin immunoprecipitation and 
QPCR revealed that histone H3 acetylation in the same CpG island was significantly 
increased in UL-1 and Ema compared to GL-1 and CLBL-1. Treatment with 5-aza 
2’-deoxycytidine or trichostatin A increased ABCB1 mRNA expression in GL-1 and 
CLBL-1. Thus, DNA methylation and histone H3 acetylation were demonstrated to be 
involved in ABCB1 gene expression and associated with an MDR phenotype in these 
canine lymphoid tumor cell lines. 
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Introduction 
 
Lymphoma is a common hematologic neoplasm in dogs (Dobson et al., 2001) and 
a representative tumor that responds to conventional chemotherapy. However, 
lymphoma cells can acquire a multidrug resistance (MDR) phenotype after or during 
chemotherapy in many cases and long-term treatment tends to fail (Marconato, 2011). 
Therefore, the mechanisms that confer an MDR phenotype in tumor cells needs to be 
elucidated. 
There are various molecules that have been shown to be associated with an MDR 
phenotype, including P-glycoprotein (P-gp), encoded by the ABCB1 gene, which is one 
of the best characterized in human cancers (O'Connor, 2007) and veterinary oncology 
(Bergman, 2003). Overexpression of P-gp reduces the intracellular concentration of 
chemotherapeutic agents (Bergman et al., 1996) and transduction of the canine ABCB1 
gene has been reported to induce chemo-resistance in a canine culture cell line 
(Matsuura et al., 2007). Furthermore, an association between P-gp expression and the 
MDR phenotype has been reported in dogs with lymphoma (Bergman et al., 1996; Lee 
et al., 1996; Moore et al., 1995). In chapter 1 of this thesis, the association of MDR 
phenotype with the overexpression of ABCB1 gene was suggested in a proportion of the 
dogs with lymphoma. 
The mechanisms that induce overexpression of P-gp have not been well 
documented. Recent investigations have revealed epigenetic regulation that induces 
ABCB1 mRNA and P-gp expression in human tumor cells. The predominant epigenetic 
mechanisms include DNA methylation, modifications to chromatin structure, loss of 
36 
 
imprinting, and non-coding RNA (Gibney and Nolan, 2010). In terms of ABCB1, an 
inverse correlation has been observed between DNA methylation in the promoter region 
and ABCB1 mRNA expression in T-cell leukemia (El-Osta et al., 2002; Kantharidis et 
al., 1997), breast cancer (Chekhun et al., 2006; David et al., 2004), and other tumor cell 
lines (Desiderato et al., 1997; Lee et al., 2008) obtained from human patients. Similar 
negative correlation has been observed in primary tumor cells from human patients with 
acute myeloid leukemia (Nakayama et al., 1998) or bladder cancer (Tada et al., 2000). 
Histone modifications, such as acetylation of histone H3 or H4, have also been 
proposed to regulate ABCB1 mRNA expression in various human cancer cell lines 
(Baker et al., 2005; David et al., 2004; Xiao et al., 2005). Since the epigenetic 
regulation of ABCB1 gene expression has not been investigated in great depth in dogs, 
the study in this chapter was designed to examine this, via analysis of DNA methylation 
and histone H3 acetylation status in canine lymphoid tumor cell lines. 
37 
 
Materials and methods 
 
Cell lines 
Four canine lymphoid tumor cell lines were used in the current study: GL-1, a 
canine B-cell leukemia cell line (Nakaichi et al., 1996); CLBL-1, a canine B-cell 
lymphoma cell line (Rutgen et al., 2010); UL-1, a canine T-cell lymphoma cell line 
(Yamazaki et al., 2008); and Ema, a canine T-cell lymphoma cell line (Hiraoka et al., 
2009). UL-1 and Ema cell lines were established from dogs with lymphoma showing 
drug resistance after chemotherapy; however, GL-1 and CLBL-1 cell lines were 
established from dogs with leukemia or lymphoma not showing drug resistance. All cell 
lines were grown in RPMI 1640 supplemented with 10% fetal calf serum (Biowest, 
Nuaillé, France) and cultured at 37 °C in a humidified atmosphere of 5% CO2. 
 
Drug sensitivity assay 
The 50% inhibitory concentration (IC50) values for vincristine were determined for 
the four cell lines. Cells (2×10
5
 cells/mL) were cultured in a 96-well plate with various 
concentrations (0.1 – 100 ng/mL) of vincristine sulfate (Oncovin; Nippon Kayaku, 
Tokyo, Japan) for 48 h. After cultivation, cell viability was measured using the Cell 
Counting Kit-8 (Dojindo, Kumamoto, Japan) according to the manufacturer’s 
instructions. Absorbance was measured using a Model 680 Microplate Reader (Bio-Rad 
Laboratories, Hercules, CA) and IC50 values were determined. In addition, changes in 
IC50 values for vincristine were determined in UL-1 and Ema cells, co-incubated with 2 
μM ciclosporin (Cs; Wako, Osaka, Japan), an ATP-binding cassette (ABC) transporter 
inhibitor. 
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Quantification of ABCB1 mRNA by real-time quantitative polymerase chain reaction 
Expression of ABCB1 mRNA was quantified using real-time reverse transcriptase 
(RT)-polymerase chain reaction (PCR) as described in chapter 1. For normalization 
purposes, TATA box binding protein (TBP) was selected as the internal reference 
(housekeeping) gene, based on the results obtained in chapter 1. 
 
Detection of P-gp expression by Western blotting 
Whole cell lysates were extracted from each cell line using RIPA buffer (Cell 
Signaling Technology, Danvers, MA), Complete protease inhibitor cocktail (Roche, 
Basel, Switzerland) and PhosSTOP phosphatase inhibitor cocktail (Roche). Protein 
concentrations were determined using the Lowry protein assay kit (Bio-rad 
Laboratories), and the equal amount of extracted proteins were separated by SDS-PAGE 
using 12.5% gel and blotted on a PVDF membrane (Immobilon-P membrane; Millipore, 
Billerica, MA). Membranes were blocked in 5% skimmed milk/Tris-buffered saline 
with Tween20 (MP Biomedicals, Solon, OH) then incubated with primary antibodies 
against P-gp (murine monoclonal: C219, Merck Calbiochem, Billerica, MA) diluted at 
1:100, or β-actin (rabbit monoclonal: #4970, Cell Signaling Technology) diluted at 
1:1000, for 12 h at 4 C. After incubation with secondary antibodies, either horseradish 
peroxidase-labeled goat anti-mouse IgG (1:5000; GE Healthcare, Tokyo, Japan) or 
donkey anti-rabbit IgG (1:10000; GE Healthcare), for 1 h at room temperature, positive 
immunoreactivity was detected using Luminata Forte Western HRP Substrate 
(Millipore) and visualized using a ChemiDoc XRS Plus (Bio-Rad Laboratories). 
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Rhodamine 123 efflux test 
One million cells of each cell line were incubated in triplicate with 200 ng/mL of 
Rhodamine 123 (Sigma-Aldrich, Zwijndrecht, Netherlands) in RPMI 1640 medium at 
37 °C for 20 min. After washing in PBS, cells were incubated in Rhodamine 123-free 
medium at 37 °C for 60 min, either with or without 2 μM of Cs. After incubation, cells 
were washed with PBS, and subjected to flow cytometric analysis using a FACSCalibur 
(BD Biosciences, San Jose, CA). Cells that had not been exposed to Rhodamine 123 
were used as negative controls, and the Rhodamine 123 efflux index (REI) was 
calculated as (mean fluorescence intensities of the sample incubated with Rh123 after 
Cs minus those of the negative control) / (those of the sample incubated with Rh123 
minus those of the negative control). 
 
Analysis of the methylation profile of ABCB1 gene 
The methylation status of the CpG island within the canine ABCB1 gene was 
analyzed by bisulfite sequencing and real-time methylation-specific PCR (MSP). 
Genomic DNA was extracted from cell lines using the QIAmp DNA Blood Mini Kit 
(QIAGEN, Hilden, Germany). Bisulfite conversion was performed on 2 μg of DNA 
using a MethylEasy Xceed Rapid DNA Bisulfite Modification Kit (Takara Bio, Shiga, 
Japan). A CpG island was identified in the canine ABCB1 gene sequence (GenBank 
accession number; NC_006596) using Methyl Primer Express v1.0 software (Applied 
Biosystems, Foster City, CA). The sequences of the primer pairs are shown in Table 2-1 
and the regions examined are shown in Fig. 2-1. 
For bisulfite sequencing, 200 ng of converted DNA was amplified using Ampli Taq 
Gold DNA polymerase (Applied Biosystems) according to the manufacturer’s 
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instructions. The PCR products were inserted into a T/A cloning vector (pGEM–T Easy; 
Promega Leiden, The Netherlands) and transferred into competent Escherichia coli 
(strain DH5α). Plasmid DNA was extracted with NucleoSpin Plasmid Quick Pure 
(Macherey-Nagel, Bethlehem, PA). Sequence analysis of the extracted plasmid DNA 
was conducted using a BigDye terminator v3.1/1.1 Cycle Sequencing Kit (Applied 
Biosystems) and an Applied Biosystems 3130xl genetic analyzer (Applied Biosystems). 
Fifteen clones from each PCR product were sequenced. The methylation rate was 
calculated for each clone examined by dividing the number of methylated sites by the 
total number of CpG sites examined. The mean methylation rate of total CpG sites in 
the examined regions was then calculated for all clones analyzed. 
For real-time MSP, completely methylated and completely unmethylated DNA 
controls were prepared from the genomic DNA of UL-1 cells using the CpG 
methyltransferase M.SssI (New England Biolabs Japan, Tokyo, Japan) and an Illustra 
GenomiPhi V2 DNA Amplification Kit (GE Healthcare) according to the 
manufacturers’ instructions. The control DNA were then inserted separately into a T/A 
cloning vector (pGEM-T Easy) and transferred into competent Escherichia coli (strain 
DH5α). Assay-specific standard curves for methylated and unmethylated DNA controls 
were prepared in triplicate with serial (10×) dilution of the plasmid DNA extracted from 
recombinant bacteria Real-time MSP was performed in duplicate using an Episcope 
MSP Kit (Takara Bio) with 100 ng DNA. The absolute quantity of methylated or 
unmethylated DNA was calculated from the standard curves. The methylation rate in 
real-time MSP was calculated by dividing the mean absolute quantity of methylated 
DNA by the sum of the mean absolute quantity of methylated and unmethylated DNA 
controls. 
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Analysis of the histone H3 acetylation profile of ABCB1 gene 
Chromatin immunoprecipitation (ChIP) was performed using a SimpleChIP 
Enzymatic Chromatin IP Kit (Magnetic Beads; Cell Signaling Technology) and 
anti-acetyl histone H3 antibody (Upstate Biotechnology Lake Placid, NY) according to 
the manufacturer’s instructions. Immunoprecipitated DNA and the 2% input sample 
DNA were subjected to real-time PCR. The real-time PCR was conducted using 200 ng 
genomic DNA by the same procedure used for ABCB1 mRNA quantification. The 
sequences of the primer pairs are shown in Table 2-1 and region examined shown in Fig. 
2-1. An assay-specific standard curve with serial (5×) dilution of genomic DNA from 
the 2% input sample was prepared in triplicate. The relative quantities to 2% input 
sample were calculated from the standard curves and the final relative values for 
enrichment of histone modifications were calculated as (anti-acetyl histone H3 antibody 
bound relative quantity - normal rabbit IgG bound relative quantity) ×2 / 2% input 
sample relative quantity. Real-time PCR was performed in triplicate and the means and 
standard deviations were calculated from three independent immunoprecipitated 
samples for each cell line. 
 
Treatment with 5-aza 2’-deoxycytidine (5-aza dC) and Trichostatin A (TSA) 
The effects of DNA demethylation induced by 5-aza dC, a DNA methyltransferase 
inhibitor, and histone H3 acetylation mediated by TSA, a histone deacetylase inhibitor, 
were examined as previously described (El-Osta et al., 2002). For DNA demethylation, 
cells were incubated with 1 μM 5-aza dC (Sigma-Aldrich) for 32 h followed by two 
additional doses for 16 h. For histone H3 acetylation, cells were incubated with 25 
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ng/mL TSA (Upstate Biotechnology) for 24 h. DNA demethylation and increased 
acetylation of histone H3 within CpG island of ABCB1 gene and global acetylation of 
histone H3 were verified using real-time MSP, real-time PCR following ChIP and 
Western blotting, respectively. The extracted total RNA from these treated cells was 
subjected to real-time RT-PCR for the relative quantification of ABCB1 mRNA as 
described previously. 
 
Statistical analysis 
The non-parametric Mann-Whitney U test was used to compare relative mRNA 
expression of ABCB1 and REI. The same test was used to compare the histone H3 
acetylation profile between cell lines. All statistical tests were two-sided and performed 
using JMP version 5.0.1 (SAS Institute). For all tests, P <0.05 was used as the level of 
significance. 
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Results 
 
Sensitivity to vincristine 
The IC50 values for vincristine in GL-1, CLBL-1, UL-1 and Ema were 6.10, 6.07, 
51.2 and 75.9 ng/mL, respectively (Fig. 2-2). When cells were treated with vincristine 
plus Cs, the IC50 values for vincristine markedly decreased in both UL-1 and Ema 
(0.735 and 0.846 ng/mL, respectively). 
 
ABCB1 mRNA expression and expression of P-gp 
The amount of ABCB1 mRNA was relatively low in the two drug-sensitive cell 
lines, GL-1 and CLBL-1 (mean relative quantity; 2.08×10
-5
 and 7.77×10
-5
, respectively), 
whereas the ABCB1 mRNA values were significantly higher in the drug-resistant cell 
lines, UL-1 and Ema (mean relative quantity; 1.03 and 15.6, respectively; Fig. 2-3A). In 
Western blotting, P-gp (approximate size = 170 kD) was detected in UL-1 and Ema 
cells but not in GL-1 and CLBL-1 cells (Fig. 2-3B). 
 
Rhodamine 123 efflux test 
In the Rhodamine 123 efflux test, the dye was retained in GL-1 and CLBL-1 cells, 
whereas there was clear evidence of efflux in UL-1 and Ema cells (Fig. 2-3C). The REIs 
in GL-1, CLBL-1, UL-1 and Ema cells were 0.975 ± 0.0452, 1.02 ± 0.0303, 6.18 ± 1.14, 
and 18.5 ± 5.27, respectively. There were significant differences in REI between GL-1 
and UL-1, CLBL-1 and UL-1, and UL-1 and Ema (P <0.01, P <0.01, and P = 0.03, 
respectively). 
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Methylation profile of ABCB1 gene 
A CpG island was identified upstream of exon 2 in the canine ABCB1 gene. In 
bisulfite sequencing, regions 1 and 2 were revealed to be hypermethylated in GL-1 and 
CLBL-1 cells, although those of the UL-1 and Ema cells were hypomethylated (Fig. 
2-4). The mean (range) methylation rates of regions 1 and 2 in the GL-1 cells were 
98.6% (95.7-100%) and 93.1% (81.3-100%), respectively. Those of the CLBL-1 cells 
were 93.2% (82.6-100%) and 84.0% (81.3-93.8%), respectively. Those of the UL-1 
cells were 0 and 1.14% (0-6.25%), respectively. Those of the Ema cells were 1.63% 
(0-13.0%) and 0.417% (0-6.25%), respectively. Similar results were obtained in 
real-time MSP. The methylation rates of the CpG islands in ABCB1 gene were 98.5%, 
100%, 0.154%, 0.0651% in the GL-1, CLBL-1, UL-1, and Ema cells, respectively. 
 
Histone H3 acetylation profile of ABCB1 gene 
In ChIP assays, before the experiment, the specificity of the anti-acetyl histone H3 
antibody was examined. In Western blotting, using lysate from UL-1 cells with or 
without treatment with TSA, bands of different intensities were observed at the expected 
position (Fig. 2-5A). The proportions of immunoprecipitated DNA to that of input DNA 
were 0.81%, 1.11%, 9.22%, and 6.26% in the GL-1, CLBL-1, UL-1, and Ema cells, 
respectively (Fig. 2-5B). 
 
Effect of DNA demethylation and histone H3 acetylation 
When GL-1 and CLBL-1 cells were incubated with 5-aza dC, their DNA 
methylation rates decreased to 42.0% and 29.1%, respectively, in real-time MSP (Table 
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2-2). In addition, TSA treatment of GL-1 and CLBL-1 cells increased the rate of histone 
H3 acetylation in CpG island of ABCB1 gene in real-time PCR following ChIP by 1.6- 
and 1.2-fold, respectively (Table 2-2). Treatment with 5-aza dC significantly increased 
the amount of ABCB1 mRNA in both of the GL-1 (15.9-fold) (Fig. 2-6A) and the 
CLBL-1 (161-fold) cells (Fig. 2-6B). TSA treatment also significantly increased the 
amount of ABCB1 mRNA in both the GL-1 (120-fold; Fig. 2-6C) and the CLBL-1 
(10.4-fold; Fig. 2-6D) cells.
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Discussion 
 
In the current study, epigenetic regulation of the ABCB1 gene, through DNA 
methylation and histone H3 acetylation, was found to be different comparing two 
drug-sensitive and two drug-resistant canine lymphoid tumor cell lines. 
The IC50 values for vincristine were considerably lower in GL-1 and CLBL-1 cells 
compared with UL-1 and Ema cells. Although there has been limited studies of the 
pharmacokinetics of vincristine in dogs, the Cmax of vincristine was reported to be 21.9 
and 28.6 ng/mL in two human patients when intravenously injected at a dosage of 0.05 
mg/kg (Skolnik et al., 2006). Since the dosage of vincristine is 0.7 mg/m
2
 in 
representative chemotherapeutic protocols for canine lymphoma (Garrett et al., 2002; 
Keller et al., 1993; Moore et al., 2001), this suggests that UL-1 and Ema could be 
drug-resistant from the IC50 values obtained in the present study (51.2, and 75.9 ng/mL, 
respectively). 
In real-time RT-PCR, ABCB1 mRNA expression was significantly greater in the 
two drug-resistant cell lines, UL-1 and Ema, than in the two drug-sensitive cell lines, 
GL-1 and CLBL-1. In addition, P-gp was detected by Western blotting in the UL-1 and 
Ema but not in GL-1 and CLBL-1 cells. Rhodamine 123 efflux occurred only in the 
UL-1 and Ema cells, indicating that functional P-gp was expressed in these cell lines but 
not in GL-1 and CLBL-1 cells and this functional P-gp might be associated with the 
MDR phenotype of the former. 
Bisulfite sequencing and real-time MSP analysis of the CpG islands of ABCB1 
gene revealed the presence of hypermethylation in GL-1 and CLBL-1 cells and 
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hypomethylation in UL-1 and Ema cells. In addition, real-time PCR after ChIP assay 
revealed apparent histone H3 acetylation in the CpG island in UL-1 and Ema cells in 
contrast with GL-1 and CLBL-1 cells. DNA demethylation induced by 5-aza dC and 
histone H3 acetylation mediated by TSA resulted in a distinct increase of the amount of 
ABCB1 mRNA in the drug-sensitive cell lines, GL-1 and CLBL-1 cells. These results 
indicated that DNA methylation is likely associated with the transcriptional silencing of 
ABCB1 gene, and histone H3 acetylation upregulated the ABCB1 gene expression in 
canine lymphoid tumor cell lines. Methylation of cytosine of CpG within CpG island in 
promoter region correlates with the transcriptional silencing of the associated gene 
(Suzuki and Bird, 2008). Whereas, histone acetylation is almost invariably associated 
with the activation of transcription (Kouzarides, 2007). An inverse correlation between 
DNA methylation of the promoter region of the ABCB1 gene and mRNA expression has 
been observed in various tumor cells (Desiderato et al., 1997; El-Osta et al., 2002; 
Kantharidis et al., 1997). Regulation of ABCB1 mRNA expression by histone H3 
acetylation has been also reported (Baker et al., 2005). Further studies should be 
conducted in tumor cells to enable to suppress the ABCB1 gene expression through 
these epigenetic regulations. 
In the current study, there were differences in epigenetic regulation of ABCB1 gene 
through DNA methylation and histone H3 acetylation between two drug-sensitive and 
two drug-resistant canine lymphoid tumor cell lines. As a further study, it should be 
examined whether similar differences are observed between primary tumor cells of 
drug-sensitive and drug-resistant dogs with lymphoid tumors. One limitation of the 
present study was that it could not be clarified that the sensitivity for vincristine was 
altered by changing DNA methylation status or histone acetylation status, because 5-aza 
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dC and TSA are both cytotoxic and therefore any cytotoxic effect of vincristine could 
not be assessed after treatment. A further limitation was that some of the parameters for 
real-time RT-PCR that should be evaluated for quality assurance purposes, such as RNA 
integrity (Bustin et al., 2009), were not measured in the present study. The 3’:5’ assay 
was not performed, although the RT reaction was conducted using Oligo dT primers that 
bind to the polyA tail at the 3’ end of mRNA. In addition, only one housekeeping gene 
was used for normalization, although the validity of using the TBP gene as a 
housekeeping gene had previously been confirmed by comparing with RPL13A and 
GAPDH genes using geNorm software in chapter 1. These deficiencies in quality 
control can potentially affect real-time RT-PCR results in studies using clinical samples, 
although are likely to have less impact when using material derived from cultured cell 
lines, where sample processing and analysis are consistent and standardized. 
In conclusion, DNA methylation and histone H3 acetylation in the CpG island of 
ABCB1 gene were associated with regulation of ABCB1 mRNA expression in canine 
lymphoid tumor cell lines. Further studies should be conducted in primary tumor cells 
to investigate whether changes in these epigenetic regulations might be associated with 
the acquisition of MDR phenotype in canine lymphoid tumor patients. 
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Table 2-2. 
Changes in the DNA methylation rates and histone H3 acetylation rates after treatment with 
5-aza 2’-deoxycytidine (5-aza dC) or Trichostatin A (TSA) in two drug-sensitive cell lines, 
GL-1 and CLBL-1. 
Cell line 
  
No treatment 
Treatment with 
 
5-aza dC TSA 
GL-1 
DNA methylation rate 
(%) 
98.5 42.0 - 
histone H3 acetylation rate 
(fold change) 
1 - 1.6 
CLBL-1 
DNA methylation rate 
(%) 
100 29.1 - 
histone H3 acetylation rate 
(fold change) 
1 - 1.2 
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Fig. 2-1. CpG sites upstream of canine ABCB1 exon 2 and the position of the regions examined 
by bisulfite sequencing, MSP and RT-PCR after ChIP assay. Each vertical line represents a CpG 
site. The numbers in the boxes and parenthesis indicate the nucleotide numbers registered in 
GenBank (NC_006596.). 
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Fig. 2-2. Dose-response curve of the cytotoxic effect of vincristine in the GL-1, CLBL-1, UL-1, 
and Ema cells. Cell viability data were plotted against the log of vincristine concentrations. Data 
represent the mean ± SD of triplicate cultures. Cs: cyclosporine (ABC transporter inhibitor). 
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Fig. 2-3. ABCB1 mRNA and P-gp expression and the functional analysis of P-gp in the four 
canine lymphoid tumor cell lines. (a) The expression level of ABCB1 mRNA was significantly 
higher in the UL-1 and Ema cells than in the GL-1 and CLBL-1 cells. *P <0.01. (b) In Western 
blotting, P-gp expression (approximate size = 170 kD) was detected in the UL-1 and Ema cells 
but not in the GL-1 and CLBL-1 cells. (c) Efflux of the Rhodamine 123 dye (Rh123) was scant 
in the GL-1 and CLBL-1 cells, whereas its efflux was obvious in the UL-1 and Ema cells. 
Inhibition of the efflux by the treatment with Cs indicates the action of functional P-gp. 
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Fig. 2-4. Methylation status of the CpG sites in regions 1 and 2 within the ABCB1 gene, 
examined by bisulfite sequencing analysis in the GL-1 (a), CLBL-1 (b), UL-1 (c), and Ema (d) 
cells. The CpG island of ABCB1 gene was hypermethylated in the GL-1 and CLBL-1 cells, 
although those in the UL-1 and Ema cells were hypomethylated. Each box represents one CpG 
site. The white boxes represent methylated CpG sites, the black boxes represent unmethylated 
CpG sites, and the proportion of the white area in each box represents the methylated rate of 
each CpG site. The numbers in the box indicate the order of each CpG site within the regions. 
Numbers between boxes indicate the number of bases between CpG sites. 
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Fig. 2-5. (a) Results of Western blotting for acetyl-histone H3 and β-actin after treatment with 
trichostatin A (TSA) in UL-1. (b) Comparison of the levels of histone H3 acetylation upstream 
of ABCB1 exon 1 using real-time PCR after ChIP assay of the four canine lymphoid tumor cell 
lines. Compared with the drug-resistant cell lines (UL-1 and Ema cells), the drug-sensitive cell 
lines (GL-1 and CLBL-1 cells) exhibited lower levels of histone H3 acetylation. *P <0.01. 
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Fig. 2-6. Changes in the amounts of ABCB1 mRNA after treatment with 5-aza dC in GL-1 (a) 
and CLBL-1 (b), and those after treatment with TSA in GL-1 (c) and CLBL-1 (d). Both of the 
treatments significantly increased the amount of ABCB1 mRNA in GL-1 and CLBL-1 cells. *P 
<0.01. 
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Chapter 2-2 
 
DNA methylation profiles of the CpG island of 
ABCB1 gene in dogs with lymphoma 
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Abstract 
 
The study in this chapter examined the DNA methylation status of ABCB1 gene in 
primary tumor cells of dogs with lymphoma. Twenty-seven dogs with multicentric 
B-cell high-grade lymphoma were included, and 19 were chemotherapy-sensitive and 8 
were chemotherapy-resistant. DNA methylation profile of the CpG island of ABCB1 
gene was analyzed by bisulphite sequencing and real-time MSP in lymphoma cell 
samples. qRT-PCR for ABCB1 gene was conducted to measure the amount of its mRNA. 
Correlation between the amount of ABCB1 mRNA and the methylation rate was 
examined. As a result, the CpG island of ABCB1 gene was shown to be hypomethylated 
in most dogs in both the chemotherapy-sensitive and -resistant groups by bisulphite 
sequencing and real-time MSP. There was no significant difference in the methylation 
rate between the two groups and no significant correlation was noted between the 
methylation rate and the mRNA expression level. In conclusion, the expression of 
ABCB1 gene was not suppressed by hypermethylation of its CpG island in most dogs 
with lymphoma regardless of their chemotherapy sensitivity. 
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Introduction 
 
Lymphoma is the most common hematologic neoplasm in dogs (Dobson et al., 
2002) and a representative tumor that responds to chemotherapy. It was reported that 
treatment with chemotherapeutic agents for dogs with lymphoma resulted in high rates 
of complete remission (CR) ranging from 76.3% to 92.3% (Garrett et al., 2002; Simon 
et al., 2006). However, most of the patients with lymphoma relapse. Efficacy of rescue 
protocols is limited after acquisition of multidrug resistance (MDR) to the agents used 
in remission induction therapy. Therefore, the mechanisms that confer MDR phenotype 
to the tumor cells have been warranted to overcome the difficulties of dog lymphoma 
treatment. 
Among molecules that have been shown to induce the MDR phenotype, 
P-glycoprotein (P-gp) (coded by ABCB1 gene, and formerly called as MDR1 gene) has 
been one of the most studied molecules in humans (O'Connor, 2007) and dogs 
(Bergman, 2003; Lee et al., 1996; Moore et al., 1995). This molecule is expressed on the 
cellular membrane and efflux drugs from cytoplasm to cell exteriors. Thus, the 
overexpression of P-gp reduces the intracellular concentration of the substrate 
chemotherapeutic agents. However, the mechanisms that induce overexpression of P-gp 
are not well understood. 
Epigenetics has been intensively investigated to understand the regulation system of 
gene expression without changing the nucleotide sequence of the genome. The main 
epigenetic mechanisms include DNA methylation, modifications to chromatin structure, 
loss of imprinting, and non-coding RNA (Gibney and Nolan, 2010). Among these 
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mechanisms, DNA methylation in the CpG island is associated with silencing gene 
expression. In human medicine, an inverse correlation has been observed between DNA 
methylation in the CpG island of the promoter region of ABCB1 and mRNA expression 
in various tumor cell lines (David et al., 2004; Desiderato et al., 1997; El-Osta et al., 
2002; Kantharidis et al., 1997). In addition, similar reverse correlation was also 
observed in the primary tumor cells collected from patients with acute myeloid 
leukemia (AML) (Nakayama et al., 1998) and bladder cancer (Tada et al., 2000). These 
studies in human medicine suggested a possibility that the methylation status of the 
CpG island in its promoter region was associated with the expression level of ABCB1 
gene, thereby influencing the acquisition of the MDR phenotype in tumor cells. 
I revealed that an inverse correlation was observed between DNA methylation of 
the CpG island of ABCB1 and mRNA expression levels in canine lymphoid tumor cell 
lines in chapter 2-1. However, the epigenetic regulation of ABCB1 has not been 
explored in primary tumor cells obtained from dogs with lymphoma. The purpose of the 
study in this chapter was to analyze the DNA methylation profile of ABCB1 in the 
primary tumor cells collected from dogs with lymphoma with and without the MDR 
phenotype. 
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Materials and Methods 
 
Dogs 
Dogs referred to the Veterinary Medical Center of the University of Tokyo and 
diagnosed with multicentric lymphoma between July 1, 2008 and June 31, 2013 were 
enrolled in the present study. Diagnosis was made based on cytological examination of 
FNA samples obtained from lymph nodes using the updated Kiel classification 
(Fournel-Fleury et al., 1997). Discrimination between B-cell and T-cell lymphomas was 
defined by PCR amplification tests for the antigen receptor gene rearrangements as 
previously described (Burnett et al., 2003; Valli et al., 2006). Only dogs that were 
diagnosed with B-cell high-grade multicentric lymphoma and met the definition as 
described below were included in this study. The clinical stage was evaluated based on 
the results of physical examination, complete blood count, thoracic and abdominal 
radiographs and abdominal ultrasounds using the WHO staging criteria (Owen, 1980). 
Written consent was obtained from all dog owners prior to study enrollment. 
 
Chemotherapy 
Veterinarians measured the size of the enlarged lymph nodes with calipers at each 
admission, and the response to treatment was evaluated based on the response 
evaluation criteria for canine lymphoma (Vail et al., 2010). In the evaluation, complete 
response and partial response were seen as indicating chemotherapy-sensitive status, 
while stable disease and progressive disease were regarded as chemotherapy-resistant 
status. 
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A CHOP-based chemotherapy, UW-25 protocol (Garrett et al., 2002), was used as a 
standard multidrug combination chemotherapy protocol. However, administration of 
L-asparaginase was omitted in all cases, because L-asparaginase was reported to have 
no influence on the efficacy of the UW-25 protocol (MacDonald et al., 2005). Dogs that 
received a corticosteroid before chemotherapy were not excluded in the present study. 
 
Definition of patient groups 
Chemotherapy-sensitive dogs were defined as those who had not received any 
chemotherapeutic agent except for a corticosteroid before the application of the UW-25 
protocol and achieved complete response or partial response by week 5 of the UW-25 
protocol. Tumor cell samples were collected just prior to the chemotherapy at the initial 
consultation. Chemotherapy-resistant dogs were defined as who underwent a relapse 
after achieving a response by the UW-25 protocol and did not respond to any of the 
three chemotherapeutic agents used in the UW-25 protocol including cyclophosphamide, 
doxorubicin, and vincristine. Tumor cell samples of the chemotherapy-resistant dogs 
were collected after confirming the non-responsiveness to these three drugs. 
 
Analysis of methylation profile of ABCB1 gene 
DNA methylation profile of the CpG island in ABCB1 was analyzed using bisulphite 
sequencing and real-time MSP as introduced in chapter 2-1. Genomic DNA was 
extracted from FNA samples using QIAmp DNA Blood Mini Kit (Qiagen). Bisulphite 
conversion was performed on 2 μg DNA using MethylEasy Xceed Rapid DNA 
Bisulphite Modification Kit (TaKaRa Bio) and converted DNA was stored at -80C 
until batch analysis. Sequences of primer pairs used for bisulphite sequencing and 
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real-time MSP are shown in Table 2-3 and locations of the analyzed regions are shown 
in Fig. 2-7. In real-time MSP, two regions were examined; upstream and downstream 
regions. 
In bisulphite sequencing, 200 ng of converted DNA was amplified using Ampli Taq 
Gold DNA polymerase (Applied Biosystems) according to the manufacturer’s 
instructions. The PCR products were inserted into a T/A cloning vector (pGEM-T Easy 
Vector Systems, Promega), and transferred into competent Escherichia coli (strain 
DH5α). Plasmid DNA was extracted with NucleoSpin Plasmid Quick Pure 
(MACHEREY-NAGEL). Sequence determination of the extracted plasmid DNA was 
conducted using BigDye terminator v3.1/1.1 Cycle Sequencing Kit (Applied 
Biosystems) and Applied Biosystems 3130xl genetic analyzer (Applied Biosystems). 
Fifteen DNA clones derived from each PCR product were sequenced. Methylation rate 
was calculated for each DNA clone examined by dividing the number of methylated 
sites by the total number of CpG sites examined. The median methylation rate was then 
calculated for all DNA clones. 
In real-time MSP, both the completely methylated DNA control and completely 
unmethylated DNA control were prepared from genomic DNA of canine lymphoma cell 
line, UL-1 (Yamazaki et al., 2008), using CpG methyltransferase M.SssI (New England 
Biolabs) and illustra GenomiPhi V2 DNA Amplification Kit (GE Healthcare), 
respectively. Complete methylation and demethylation were verified by bisulphite 
sequencing as described above. These control DNAs were then inserted into a T/A 
cloning vector and transferred into competent Escherichia coli (strain DH5α). 
Assay-specific standard curves for methylated and unmethylated DNAs were prepared 
in triplicate with serial (10x) dilution of plasmid extracted from the Escherichia coli. 
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Real-time MSP was performed in duplicate using an Episcope MSP Kit (TaKaRa Bio) 
and Thermal Cycler Dice Real Time System TP800 (TaKaRa Bio) with 100 ng of DNA. 
The absolute quantity of methylated or unmethylated DNA was calculated from the 
standard curves. Methylation rate in real-time MSP was calculated by dividing mean 
absolute quantity of methylated DNA by the sum of mean absolute quantity of 
methylated and unmethylated DNA. 
 
qRT-PCR 
For estimation of the relative quantity of mRNA of ABCB1 gene, qRT-PCR was 
performed as described in chapter 1. Total RNA was extracted from each FNA samples 
using RNAqueous (Ambion) and stored at -80C until batch analysis. After treatment 
with DNase (DNase I, Invitrogen), cDNA was synthesized with total RNA using 
PrimeScript RT reagent Kit (Perfect Real Time). The same primer pair for qPCR of 
ABCB1 gene expression was used as in chapter 1 (Table 2-3). For normalization of the 
amount of cDNA sample, TBP gene was selected as the internal reference based on 
result of chapter 1. qPCR was performed using SYBR Premix Ex Taq II (Perfect Real 
Time) and Thermal Cycler Dice Real Time System TP800 (TaKaRa Bio) with cDNA 
synthesized from 10 ng of total RNA. For each gene, an assay-specific standard curve 
with serial (10x) dilution of cDNA from UL-1 cells was prepared in triplicate. The 
relative expression level of ABCB1 calculated from the standard curve was divided by 
that of TBP gene for normalization. qRT-PCR was performed in triplicate. 
 
Statistical analysis 
Correlation of the methylation rate in the CpG island of ABCB1 gene with the relative 
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quantity of mRNA was examined using the Spearman’s rank correlation test. The 
Mann-Whitney U-test was used for comparison of the methylation rate between 
chemotherapy-sensitive and -resistant dogs. Values of P < 0.05 were considered to be 
significant. Statistical analysis was performed with a commercially available software 
(JMP version 5.0.1, SAS Institute).
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Results 
 
Dogs 
Twenty-seven dogs with B-cell high-grade multicentric lymphoma were included in 
the study in this chapter. Breeds included Welsh Corgi Pembroke (4), Pug (3), Miniature 
Dachshund (3), Golden Retriever (2), Shiba Inu (2), French Bulldog (2), and Beagle (2), 
and 1 each of Shih Tzu, Doberman, mixed, Bulldog, Bernese Mountain Dog, Scottish 
Terrier, Pomeranian, West Highland White Terrier, and Australian Kelpie. The median 
age was 8 years (range, 2 to 13 years) and the median body weight was 10.9 kg (range, 
4.2 to 33.0 kg). There were 8 female (4 spayed) and 19 male (7 castrated) dogs. 
Lymphoma was classified based on WHO clinical stage as stage II in 1 dog, stage III in 
3 dogs, stage IV in 8 dogs, and stage V in 15 dogs, and WHO substage a in 17 dogs and 
substage b in 10 dogs. Based on the definition of patient groups, 19 dogs were included 
in the chemotherapy-sensitive group and 8 dogs were included in the 
chemotherapy-resistant group. Records of corticosteroid administration before 
chemotherapy were found in 3 of the 27 dogs with lymphoma. In these 3 dogs, 
prednisolone was orally administrated at 1 mg/kg/day for 6 days, 1mg/kg/day for 16 
days, and 2mg/kg/day for 3 days, respectively. 
Bisulphite sequencing- Among dogs included, 4 dogs were randomly selected from 
each group, and DNA methylation profiles of the CpG island of ABCB1 gene in the 
tumor cells were analyzed in detail using bisulphite sequencing. In a 
chemotherapy-sensitive patient, dog 1, DNA methylation rate was consistently more 
than 50% in all of the 23 CpG sites of ABCB1 gene (Fig. 2-8). On the contrary, most of 
the 23 CpG sites were hypomethylated in 2 chemotherapy-sensitive dogs (dogs 3 and 4). 
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Another chemotherapy-sensitive patient, dog 2, showed an intermediate DNA 
methylation pattern. In a chemotherapy-resistant patient, dog 5, degree of DNA 
methylation was variable among the 23 CpG sites of ABCB1 gene. However, most of 
the 23 CpG sites were unmethylated in 3 chemotherapy-resistant patients (dogs 6, 7, and 
8). There was no apparent difference in the methylation rates of CpG sites between the 
chemotherapy-sensitive and chemotherapy-resistant groups. Moreover, the methylation 
profile of each CpG site varied among 15 DNA clones derived from each patient of both 
groups.  
Real-time MSP- DNA methylation profiles were also analyzed using real-time MSP 
in 19 chemotherapy-sensitive dogs and 8 chemotherapy-resistant dogs. In the upstream 
region of the CpG island of ABCB1, methylation rates were lower than 15% in 17 of 19 
chemotherapy-sensitive dogs, and the median (range) of methylation rates was 0.409% 
(0-14.1%) in these dogs, although methylation rates in 2 dogs were more than 50% 
(57.2% and 90.2%) (Fig. 2-9A). In the chemotherapy-resistant group, methylation rates 
in the upstream region were lower than 1.5% in 6 of 8 dogs, and the median (range) of 
methylation rates was 0.635% (0-1.42%) in these dogs, although methylation rates in 2 
dogs were more than 40% (41.7% and 59.4%). 
Similarly, in the downstream region of the CpG island, methylation rates were lower 
than 10% in 18 of 19 chemotherapy-sensitive dogs, and the median (range) of 
methylation rates was 0.332% (0-7.79%) in these dogs, although methylation rate in 1 
dog was 55.2% (Fig. 2-9B). In chemotherapy-resistant group, methylation rates in 
downstream region were lower than 2% in 6 of 8 dogs, and the median (range) of 
methylation rates was 0.276% (0-1.98%) in these dogs, although methylation rates in 2 
dogs were more than 40% (41.5% and 66.0%). There was no significant difference in 
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the methylation rate between chemotherapy-sensitive and -resistant dogs in either the 
upstream or downstream region (P = 0.82 and 0.48, respectively). 
Relative quantity of ABCB1 gene mRNA- qRT-PCR was examined using FNA 
samples of 16 chemotherapy-sensitive dogs. The ABCB1 mRNA was detected in all 16 
dogs. However, there was no significant correlation between the methylation rate of the 
CpG island obtained in real-time MSP examination and the relative quantity of ABCB1 
mRNA in both the upstream and downstream regions (ρ2 = 0.00038 and 0.022, and P = 
0.94 and 0.57, respectively) (Fig. 2-10). 
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Discussion 
 
In the present study, the DNA methylation status of ABCB1 was analyzed by using 
bisulphite sequencing and real-time MSP in dogs with lymphoma. 
In bisulphite sequencing, methylation rates were variable among 8 dogs examined, 
and the DNA methylation profile of each CpG site varied among 15 DNA clones 
derived from each patient. These results raised a possibility that canine lymphoma 
tissues might be composed of a heterogeneous population with various methylation 
profiles of CpG sites of ABCB1. In a previous study in humans, the DNA methylation 
profile of ABCB1 gene was analyzed using bisulphite sequencing in tumor cells of AML 
patients before chemotherapy (Fryxell et al., 1999). The study indicated that the DNA 
methylation status was different among patients in a subset of CpG sites of the CpG 
island and agree with the results obtained from the present study. However, methylation 
patterns of the CpG sites were similar among DNA clones derived from human patients 
with AML. The disagreement compared with the results in the study of this chapter in 
canine lymphoma might be due to the difference in the number of DNA clones analyzed 
in bisulphite sequences, since only 4 to 5 DNA clones from each patient were analyzed 
in the previous study (Fryxell et al., 1999). 
In real-time MSP, CpG sites of ABCB1 gene examined in this study were not 
methylated in most of the tumor cells obtained from dogs with lymphoma, regardless of 
sensitivity for chemotherapy, and there was no significant difference in methylation rate 
between the chemotherapy-sensitive and -resistant dogs. It was reported that ABCB1 
was in a hypermethylated state in 66% of human AML patients who achieved CR by 
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chemotherapy when examined by PCR with methylation-sensitive restriction enzymes 
(Nakayama et al., 1998). Although the methylation rates of CpG island of ABCB1 gene 
in chemotherapy-sensitive lymphoma dogs were lower compared to the rates in the 
human AML patients, the reason for the difference was not clear. Another study 
examined the methylation status of ABCB1 in human hematopoietic malignancy 
patients including 5 patients with non-Hodgkin’s lymphoma, but the methylation status 
of the gene in these non-Hodgkin’s lymphoma patients was not described in detail (Shi 
et al., 2011). Since it is thought that canine lymphoma shares many similarities with 
human non-Hodgkin’s lymphoma (Vail and MacEwen, 2000), further studies that 
compare the DNA methylation status of ABCB1 gene between human and canine 
lymphoma cells might help to utilize canine lymphoma as a spontaneous animal model 
of human non-Hodgkin’s lymphoma. 
In this study, there was no significant correlation between the amount of ABCB1 
gene mRNA and methylation rate in real-time MSP. I revealed that DNA methylation in 
the CpG island regulated the expression of ABCB1 gene mRNA in canine lymphoma 
cell lines in chapter 2-1, and the gene expression of ABCB1 gene was silenced in cell 
lines with hypermethylated ABCB1 gene. In the present study, qRT-PCR was conducted 
by the same method as used in chapter 2-1, and the expression levels of ABCB1 gene in 
canine primary lymphoma cells in the present study were markedly higher than those in 
canine cell lines with hypermethylated ABCB1 gene, including CLBL-1, derived from 
dogs with B-cell high-grade multicentric lymphoma. Therefore, it was possible that 
ABCB1 gene was in a hypomethylated state and the expression of this gene was not 
silenced in tumor cells of chemotherapy-sensitive dogs. This might be the reason for no 
correlation between relative quantities of ABCB1 gene mRNA and methylation rates 
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calculated from the results of real-time MSP. 
As shown in chapter 2-1, DNA methylation is involved in the regulation of canine 
ABCB1 gene expression. However, the expression of ABCB1 gene was not silenced by 
DNA methylation in canine lymphoma patients before chemotherapy in the study in this 
chapter. This observation suggests that mechanisms other than DNA demethylation 
might play a major role when lymphoma cells acquire the increased expression of 
ABCB1 gene. 
One limitation in the present study was that the number of chemotherapy-resistant 
dogs was small because the resistance for all three chemotherapeutic agents could not 
be confirmed in a certain number of dogs due to the rapid progress of lymphoma. 
As another limitation, the expression level of ABCB1 gene was not examined in the 
primary tumor cells obtained from dogs with chemotherapy-resistant lymphoma. It was 
unclear whether overexpression of ABCB1 gene occurred and what mechanisms induced 
the MDR phenotype in chemotherapy-resistant patients included in the present study. 
In conclusion, the present study indicated that canine lymphoma tissues contained 
a heterogeneous population with various methylation profiles of CpG sites of ABCB1 
gene. Moreover, it was also shown that the CpG island of ABCB1 gene was not in 
hypermethylated state and expression of this gene was not silenced in most of the dogs 
with lymphoma, regardless of their different chemotherapy sensitivity. 
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Fig. 2-7. CpG island in canine ABCB1 gene and the locations of the regions examined by 
bisulphite sequencing and real-time MSP. Each gray vertical line represents a CpG site. The 
numbers in the boxes and parenthesis indicate the nucleotide numbers registered in GenBank 
(NC_006596). 
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Fig. 2-8. DNA methylation profiles of CpG sites of ABCB1 gene in chemotherapy-sensitive 
dogs (A, Dog Nos. 1-4) and -resistant dogs (B, Dog Nos. 5-8). Each box represents one CpG 
site. The white represents methylated CpG sites and black represents unmethylated CpG sites, 
and the rate of area of white in each box represents the rate of DNA clones with methylated 
cytosine in each CpG site. Numbers in the box indicate the order of each CpG site within 
regions. Numbers between boxes indicate the number of bases between CpG sites. The median 
(rages) of methylation rates in chemotherapy-sensitive dogs were 74.5% (0-100%) in dog 1, 
46.6% (8.7-69.6%) in dog 2, 11.7% (0-65.2%) in dog 3 and 7.36% (0-17.4%) in dog 4, and 
those in chemotherapy-resistant dogs were 54.3% (0-87.0%) in dog 5, 7.36% (0-17.4%) in dog 
6, 5.14% (0-13.0%) in dog 7 and 0.932% (0-4.35%) in dog 8, respectively. 
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Fig. 2-9. Methylation rates of ABCB1 gene in the upstream (A) and downstream (B) CpG motifs 
of ABCB1 gene in chemotherapy-sensitive dogs (n=19) and -resistant dogs (n=8). 
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Fig. 2-10. Correlation of methylation rates of ABCB1 gene with the relative quantities of 
ABCB1 mRNA in chemotherapy-sensitive dogs. There was no significant correlation between 
these two parameters in both of the upstream (A) and downstream (B) regions of CpG island (ρ2 
= 0.00038 and 0.022, and P = 0.94 and 0.57, respectively). 
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Chapter 3 
 
Regulation of ABCB1 and LRP genes through 
MAPK/ERK pathway in canine lymphoma cell lines 
78 
 
 
Abstract 
 
Cancer stem cell (CSC) concept has been recognized as a key for elucidation of the 
mechanisms that confer the MDR phenotype to tumor cells, and side population (SP) 
fraction has been shown to be enriched by cells with CSC phenotype. The purpose of 
the study in this chapter was to indicate mechanism that induces the difference of 
phenotype between SP and other population (major population; MP) using 2 canine 
lymphoma cell lines. Expression levels of ABCB1 and LRP genes, which encode efflux 
pumps, were significantly higher in SP than MP. Microarray analysis revealed the 
upregulation of expression of TGF-β type II receptor gene in SP compared with MP, and 
MAPK/ERK pathway was more activated in SP than MP. Stimulation of MAPK/ERK 
pathway significantly increased the mRNA expression of both of ABCB1 and LRP 
genes. These results indicated the increased expression of the efflux pumps through 
MAPK/ERK pathway in SP cells. 
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Introduction 
 
Multidrug resistance (MDR) is one of the major obstacles during the chemotherapy 
in the patients with various cancers. Although a lot of molecules that contribute to the 
development of MDR have been reported (Gimenez-Bonafe et al., 2009; Harris and 
Hochhauser, 1992), the mechanisms of acquisition of MDR in tumor cells are not well 
understood. 
Cancer stem cell (CSC) has recently been considered as the key for elucidation of 
the mechanisms of acquisition of MDR in various tumors (Baguley, 2010). In this 
concept, it is thought that a small population with stem cell-like characteristics is 
initially resistant to conventional chemotherapy and these cells are cause of relapse and 
acquisition of MDR. Therefore, the clarification of the mechanisms that confer MDR 
phenotype to CSC is important for elucidation of the mechanisms of acquisition of 
MDR in tumor tissues. 
The Hoechst 33342 dye exclusion test is one of the methods to detect stem cells 
from various normal and tumor tissues (Moserle et al., 2010). Although uptake of this 
reagent occurs universally in all cells, efflux is less permissive. Only a small population 
of cells shows high potency to exclude the dye. These cells are referred to as side 
population (SP) and are distinguished from the remaining major population (MP). SP 
has been identified and characterized in various tumors including non-Hodgkin’s 
lymphoma such as human follicular lymphoma (Lee et al., 2012) and murine mantle cell 
lymphoma model (Vega et al., 2010), and SP in tumor cell lines and primary tumor cells 
have been shown to be enriched by CSC (Moserle et al., 2010). SP is considered to 
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efflux the dye using highly expressed ABC transporter family members such as 
P-glycoprotein (P-gp) and ABCG2 (Hadnagy et al., 2006; Wu and Alman, 2008). SP has 
been shown to have MDR phenotype and such high efflux potency is thought to be the 
mechanism to confer MDR phenotypes on SP (Zhang et al., 2010). Therefore, it might 
be important to study on mechanisms that activate the expression of these efflux pumps 
in SP. However, such mechanisms have not been clarified. 
As in human medicine, SP has been identified in canine lung adenocarcinoma 
(Nemoto et al., 2011) and mammary tumor cells (Ferletta et al., 2011), and it was shown 
that these SP possessed stem cell-like characteristics. However, the mechanisms that 
confer MDR phenotype upon SP have been unclear. In addition, SP in canine lymphoma 
cells has not been identified. 
In chapter 2, it was revealed that epigenetic regulation was associated with the 
regulation of ABCB1 gene expression, but DNA methylation was not associated with the 
acquisition of MDR phenotype in canine lymphoma cells. Therefore, other mechanisms 
than epigenetic regulations should be investigated to elucidate the mechanisms that 
induce overexpression of drug efflux pumps in canine MDR lymphoma cells. 
The purpose of the study in this chapter was to identify SP in canine lymphoma 
cell lines and to reveal the mechanisms that activate the expressions of efflux pumps in 
SP. Furthermore, more detailed mechanisms that activate the function of the efflux 
pumps were tried to be clarified.
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Materials and Methods 
 
Cell cultures 
In the present study, 2 canine T-cell lymphoma cell lines, UL-1 (Yamazaki et al., 
2008) and Ema (Hiraoka et al., 2009), were used. These cell lines were cloned from a 
single cell using the limit dilution method before using in the following experiments, 
and grown in RPMI 1640 supplemented with 10% fetal calf serum and cultured at 37 °C 
in a humidified atmosphere of 5% CO2. 
 
Hoechst 33342 dye efflux test 
SP were detected as previously described (Arends et al., 2009). Briefly, cells were 
incubated in the presence of 5 μg/mL Hoechst 33342 (Sigma-Aldrich, Zwijndrecht, 
Netherlands) for 90 min. Another set of cells was pre-incubated with the transport 
blocker, reserpine (50 μM; Sigma-Aldrich), for 20 min before Hoechst 33342 
incubation. After washing, Hoechst 33342-stained cells were resuspended in ice-cold 
phosphate buffered saline containing 2mM EDTA and 1μg/mL propidium iodide (PI; 
Sigma-Aldrich), and kept on ice before and during fluorescence-activated cell sorting 
(FACS) analysis using FACSAria (BD Biosciences, San Jose, CA, USA). After analysis, 
SP and MP were sorted separately. 
 
Relative quantification of mRNA of efflux pumps 
In the comparison of expression level of efflux pumps between sorted SP and MP, 
the expressions of ABCB1, ABCC1, LRP and ABCG2 genes were analyzed in the 
present study. The efflux pumps coded by ABCB1, ABCC1 and ABCG2 genes are 
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known as representative ABC-transporters associated with acquisition of multidrug 
resistance in tumor cells (Modok et al., 2006). LRP has different function from these 
efflux pumps and redistributes drugs from the nucleus to the cytoplasm because it is 
expressed on nuclear membrane (Gromicho et al., 2011). For the comparison of the 
expressions of these efflux pumps between SP and MP, mRNA of ABCB1 (coding P-gp), 
ABCC1, LRP and ABCG2 were relatively quantified using real-time reverse 
transcriptase (RT)-polymerase chain reaction (PCR) as described in chapter 1 using the 
same primer pairs (Table 3-1). For normalization of the amount of cDNA sample, TATA 
box binding protein (TBP) gene was used as an internal reference based on the result 
obtained in chapter 1. The fold-change in relative quantity of each gene mRNA of SP 
were calculated by comparing with that of MP. Real-time RT-PCR was performed in 
triplicate. 
 
Cell-cycle analysis 
Cell cycles of sorted SP and MP cells were analyzed by calculating DNA content. 
Cells were fixed and permeabilized using BD cytofix/Cytoperm Kit (BD biosciences), 
and stained with 7-amino-actinomycin D (BD Biosciences). Flow cytometric analysis 
was performed with FACSCalibur (BD Biosciences). The cell-cycle analysis was 
conducted using Flowjo software (TreeStar, Ashland, OR, USA). 
 
Microarray analysis 
Total RNA was isolated from sorted SP and MP using RNeasy Mini Kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s instruction. The RNA quantity and 
qualtiy were assessed using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
83 
 
Clara, CA, USA) and RNA integrity numbers were confirmed as above 9.0. The 
synthesis of cDNA and Cy3 or Cy5 labelled cRNA were conducted using Quick Amp 
Labeling Kit (Agilent Technologies) and RNA spike-In two-color Kit (Agilent 
Technologies). The cRNA derived from SP were labelled with Cy3, and that derived 
from MP were labelled with Cy5. The labelled cRNAs were purified using RNeasy 
Mini Kit (QIAGEN), and fragmented and hybridized to Canine ver.2 (4×44K) array 
(Agilent Technologies) using Gene Expression Hybridization Kit (Agilent 
Technologies). After hybridization, slide was washed with Gene Expression Wash 
(Agilent Technologies), and was scanned using High-Resolution Microarray Scanner 
(Agilent Technologies). All image and data analysis were conducted using Feature 
Extraction software (Agilent Technologies). Spots of compromised quality and with low 
intensity were eliminated from the analysis. The data was normalized by LOWESS 
method, and Cy5:Cy3 ratios and log2 values of those were calculated. Filtering and 
complication of data were conducted using Microsoft Excel. Only those genes, which 
showed log2 values greater than 1 (0.5-fold downregulated in SP) or less than -1 (2-fold 
upregulated in SP) and consistent regulation in UL-1 and Ema, were included in 
analysis. Among such genes, the fold change of TGF-β type II receptor gene was 
confirmed using real-time RT-PCR with primer pair listed in Table 3-1 as described 
above. 
 
Western blotting for Smad pathway and MAPK/ERK pathway 
For comparison of activation of TGF-β signalling between SP and MP, Western 
blotting for Smad pathway and MAPK/ERK pathway were examined. SP and MP of 
Ema were sorted as described above. Then, whole cell lysates were extracted from each 
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cells, and equal amounts of protein were separated by SDS-PAGE and blotted onto a 
PVDF membrane as in chapter 2-1. Membranes were blocked in 5%-skimmed 
milk/tris-buffered saline with Tween20, and then incubated with primary antibody 
against phospho-Smad2/Smad3 (diluted at 1:500), Smad2 (1:1000), Smad3 (1:1000), 
Smad4 (1:1000), phospho-p44/42 (ERK1/2) (1:2000), p44/p42 (ERK1/2) (1:1000) and 
β-actin (1:1000) (Cell Signaling Technology) overnight at 4 C. After incubation with 
the secondary antibody of horseradish peroxidase-labeled anti-rabbit IgG (1:3000; 
Bio-rad Laboratories) for 1 h at room temperature, positive immunoreactivity was 
detected using Luminata Forte Western HRP Substrate (Millipore) and visualized using 
ChemiDoc XRS Plus (Bio-rad Laboratories). 
 
Activation of MAPK/ERK pathway 
For activation and MAPK/ERK pathway and its inhibition, phorbol 12-myristate 
13-acetate (PMA) (Wako, Osaka, Japan), protein kinase C (PKC) activator, and U0126 
(Promega, Leiden, Netherlands), MAPK/ERK kinase (MEK) inhibitor, were used as 
previously described (Yang et al., 2001; Zhang et al., 2011). Briefly, UL-1 and Ema and 
these cells pre-incubated with 10 μM U0126 for 1 h were incubated with 200 nM PMA 
for 8 h, and the relative quantity of ABCB1 and LRP genes mRNA of these cells were 
compared with non-treated cells using real-time RT-PCR as described above. The 
fold-change in relative quantity of each gene mRNA of treated cells were calculated by 
comparing with that of non-treated cells. The increase of phospho-p44/p42 (ERK1/2) by 
PMA and its inhibition by U0126 were verified using Western blotting as described 
above. 
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Changes in rates of SP through activation of MAPK/ERK pathway 
To examine the regulation of SP phenotype through activation of MAPK/ERK 
pathway, the rates of SP were analyzed after incubation with PMA or both of PMA and 
U0126. Briefly, UL-1 and Ema cells (pretreated with 10 μM U0126 for 1 h or 
non-treated) were cultured in the presence of 200 nM PMA for 24 h. After wash with 
appropriate culture medium, the rates of SP cells were analyzed as described above, and 
these rates were compared with those in non-treated cells. These analysis were 
examined in three independent assays. 
 
Statistical analysis 
The nonparametric Mann-Whitney U-test was used for comparison of relative 
quantities of genes. The same test was used for comparison of the rate of cells that were 
in G0/G1 phase and comparison for the rates of SP. All statistical tests were two-sided 
and performed using JMP version 5.0.1 (SAS Institute, Cary, NC, USA). For all tests, p 
< 0.05 was used as the level of significance.
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Results 
 
Identification of SP 
In the Hoechst 33342 dye exclusion test, a distinct population that apparently 
effluxed the dye was observed in both of UL-1 and Ema (Fig. 3-1A and B, respectively). 
This population was identified to be SP, as preincubation with reserpine resulted in the 
loss of this population of cells in both of UL-1 and Ema (Fig. 3-1C and D, respectively). 
The percentage of SP in UL-1 and Ema ranged from 0.79 to 1.23% and 10.5 to 16.1%, 
respectively, in three independent assays. 
 
ABCB1 and LRP genes were upregulated in SP 
Among the 4 genes encoding efflux pumps, the amounts of ABCB1 and LRP gene 
transcripts were shown to be significantly higher in SP than MP in both of UL-1 and 
Ema (p < 0.01) (Table 3-2). No significant difference was observed in the amount of 
ABCC1 gene transcript in both of UL-1 and Ema. The expression of ABCG2 gene was 
not detected in Ema and its amount was not different between SP and MP of UL-1. 
 
Most of SP were in G0/G1 phase 
Although 61.0±2.7% of MP were in G0/G1 phase, 93.5±4.9% of SP were in the 
G0/G1 phase in UL-1 (Fig. 3-2A) in cell cycle analysis. Also in Ema, 97.1±0.2% of SP 
were in the G0/G1 phase, whereas 54.1±3.0% of MP were in G0/G1 phase (Fig. 3-2B). 
In both of two cell lines, the rates of cells that were in G0/G1 phase were significantly 
larger in SP than MP (p < 0.01). 
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TGF-β type II receptor gene expression was upregulated in SP than MP 
In microarray analysis, 86 spots (82 genes) whose expressions were upregulated in 
SP (Table 3-3) and 33 spots (31 genes) whose expressions were downregulated in SP 
(Table 3-4) were sorted. Among these sorted genes, TGF-β type II receptor gene, which 
was highly expressed in SP than MP in both of UL-1 and Ema, was focused because 
TGF-β signaling was reported to be correlated with SP phenotype in human tumor cell 
lines (Kabashima et al., 2009; Yin et al., 2008). Therefore, the upregulation of TGF-β 
type II receptor gene expression was validated using real-time RT-PCR. Also in 
real-time RT-PCR, the relative mRNA quantity of the gene in SP was significantly 
higher than MP in both of UL-1 and Ema (p < 0.01) (Table 3-2). 
 
MAPK/ERK pathway was more activated in SP than MP 
As downstream of TGF-β signaling, Smad pathway and MAPK/ERK pathway 
were focused, and the activation states of these pathways were compared between SP 
and MP of Ema.  When Western blotting for Smad pathway was performed, the 
quantities of phospho-Smad2 and Smad4 of SP were not different compared with MP 
(Fig. 3-3A). Smad3 and phospho-Smad3 were not detected in both of SP and MP. 
However, in Western blotting for MAPK/ERK pathway, the quantities of 
phopho-p44/p42 (ERK1/2) were found to be larger in SP than MP (Fig. 3-3B).  
 
MAPK/ERK pathway regulated the expression of ABCB1 and LRP genes 
When UL-1 and Ema were incubated with PMA, the quantities of 
phosphor-p44/p42 (ERK1/2) were increased compared with non-treated cells (Fig. 3-4). 
This effect of PMA was inhibited by pre-incubation with U0126. After incubation with 
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PMA for 8 h, the relative quantity of ABCB1 (Fig. 3-5A) and LRP (Fig. 3-5B) mRNAs 
were significantly increased compared with non-treated cells in both of UL-1 and Ema 
(p < 0.01). When cells were pre-incubated with U0126 before incubation with PMA for 
8 h, the relative quantity of ABCB1 and LRP genes mRNA were significantly smaller 
compared with cells incubated with PMA alone in both of UL-1 and Ema (p = 0.02 in 
ABCB1 genes of UL-1 and p < 0.01 in others). 
 
PMA stimulation increased the rates of SP 
Finally, changes of the rates of SP by PMA stimulation were examined. The rates 
of SP were significantly increased through PMA stimulation in both of UL-1 and Ema 
(44.7±6.40%; p < 0.01 and 56.7±4.36%; p < 0.01) compared with non-treated cells (Fig. 
3-6). When the cells were pretreated with U0126, a MAPK/ERK inhibitor, this increase 
in rates of SP was significantly inhibited in Ema (28.8±6.42%; p < 0.01), although such 
inhibition by the treatment with U0126 was not observed in UL-1 (38.6±9.74%; p = 
0.37).
89 
 
Discussion 
 
For elucidation of mechanisms which confer the MDR phenotype on cancer cells, 
two major models have been proposed; one is ‘activation model’ (Hu et al., 1999), and 
another is ‘selection and expansion model’ (Goldie and Coldman, 1984). The former 
proposes that chemotherapeutic drugs directly activate the mechanisms which confer the 
MDR phenotype. The latter describes that small MDR population expands by 
drug-induced selection, and eventually overgrows residual drug-sensitive population. 
However, which model truly reflects the mechanisms of MDR acquisition has been 
unclear. CSC concept, in which a small population is initially resistant to conventional 
chemotherapy, supports the latter model. In the present study, SP fraction that has been 
shown to be enriched with cells with CSC phenotype in various tumor cells was 
identified in clonal canine lymphoma cell lines. In addition, the regulation of the 
expression of ABCB1 and LRP genes through MAPK/ERK pathway was revealed, and 
the possibility was shown that SP possessed more drug-resistant phenotype compared 
with MP by activating MAPK/ERK pathway in a certain type of canine lymphoma cells. 
Real-time RT-PCR showed that the expression levels of ABCB1 and LRP genes 
were significantly higher in SP than MP in both of UL-1 and Ema. These results 
indicated that P-gp and LRP might have an important role in the efflux of Hoechst 
33342 dye. In previous studies, SP was suggested to efflux the dye using highly 
expressed ABC transporter family members, such as P-gp and ABCG2 (Hadnagy et al., 
2006; Wu and Alman, 2008). However, there has been no study that indicates high 
expression level of LRP in SP. LRP, also named as major vault protein (MVP), is 
expressed on nuclear membrane, and associated with redistribution of the drug from the 
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nucleus to the cytoplasm (Gromicho et al., 2011). The results in the present study 
indicated that LRP played a key role in efflux of Hoechst dye from nuclear to cytoplasm, 
because ABC transporter such as P-gp and ABCG2 are expressed in cell membrane. In 
addition, it is possible that SP were more drug-resistant compared with MP, as P-gp and 
LRP have been reported to be important factors associated with drug resistance in 
human lymphoma patients (Valera et al., 2004). 
Besides the expression level of efflux pump, the distribution of cell-cycle of SP 
was different from that of MP. In both of UL-1 and Ema, most of SP was in G0/G1 
phase compared with MP. These results indicated that SP are generally in the quiescent 
state while MP are actively proliferating. It can also be assumed that SP was more 
resistant to chemotherapy than MP, because the chemotherapeutic agents generally have 
a more cytotoxic effect in actively proliferating cells than stable cells. Indeed, a 
previous study on lung cancer cell line showed that SP, which were mainly in a 
quiescent state, showed apparent resistance to chemotherapeutic agents such as 
doxorubicin and cisplatin (Ho et al., 2007). 
To clarify the mechanisms that induced the difference of phenotype between SP 
and MP, comprehensive gene expression analysis using microarray and verification with 
real-time RT-PCR were examined, and upregulation of TGF-β type II receptor gene 
expression in SP was focused. In addition, activations of Smad and MAPK/ERK 
pathways, which are downstream of TGF-β signaling, were compared between SP and 
MP of Ema. As a result, the quantity of phopho-p44/p42 (ERK1/2) was larger in SP than 
MP, although quantities of proteins involved in Smad pathway were not different 
between SP and MP. Furthermore, MAPK/ERK signaling was found to upregulate the 
expression of ABCB1 and LRP genes in the present study. These indicated the presence 
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of upregulated expression of ABCB1 and LRP genes through MAPK/ERK pathway in 
SP. To examine the role of MAPK/ERK in regulation of SP phenotype, changes in the 
rates of SP by PMA stimulation were analyzed. As a result, PMA stimulation increased 
the percentages of SP cells and treatment with an inhibitor of MAPK/ERK pathway, 
U0126, inhibited this increase in Ema cells. In UL-1 cells, although the percentages of 
SP cells increased by PMA stimulation, this increase was not inhibited after treatment 
with U0126. From these findings, MAPK/ERK pathway was thought to play the central 
role in regulation of SP phenotype in Ema, although other pathways activated by PMA 
stimulation might be involved in regulation of SP phenotype in UL-1. Previous studies 
showed that treatment with doxorubicin upregulated the expression of ABCB1 gene 
through MAPK/ERK pathway in human tumor cell lines (Shen et al., 2011; Yang et al., 
2001). The results in the present study were consistent with those of these previous 
studies (Shen et al., 2011; Yang et al., 2001). However, there has been no study on 
activation of MAPK/ERK pathway in SP or the correlation of this pathway with 
regulation of LRP gene expression. The results obtained in the present study suggested 
the possibility that MAPK/ERK pathway has a crucial role in the regulation of SP 
phenotype in a certain type of canine lymphoma cells, and MAPK/ERK pathway could 
be the target of therapy to overcome the tumor cells with MDR phetnotype conferred by 
the upregulation of efflux pumps such as P-gp and LRP. 
Although SP fraction in tumor cell population has been thought to be enriched by 
cells with CSC phenotype (Moserle et al., 2010), functions as the stem cells were not 
compared between SP and MP in the present study. The phenotype such as 
tumorigenesis should be examined in the future study. However, the results in the 
present study suggested that small population with enhanced MDR phenotype existed in 
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clonal cell lines. These findings might support the ‘selection and expansion model’. 
Further studies are needed to clarify whether such heterogeneous phenotypes exist of 
tumor tissue in patients and ‘selection and expansion model’ truly reflects the 
mechanisms of acquisition of MDR in vivo.  
In conclusion, the present study revealed that MAPK/ERK pathway upregulated 
the expressions ABCB1 and LRP genes in SP cells of canine lymphoma cell lines. The 
possibility should be examined in the future that the modulating of intracellular 
signalings such as MAPK/ERK pathway could decrease the expression of ABCB1 and 
LRP genes and reconstitute the sensitivity of MDR lymphoma cells to anticancer drugs.
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Table 3-2 
The fold-changes of relative amount of cDNA of each gene in side population (SP) cells 
compared with major population (MP) cells 
 
Gene UL-1 Ema 
ABCB1 
1.60-fold 
(p < 0.01) 
2.19-fold 
(p < 0.01) 
ABCC1 
1.48-fold 
(p = 0.11) 
0.69-fold 
(p = 0.08) 
LRP 
2.61-fold 
(p < 0.01) 
3.57-fold 
(p < 0.01) 
ABCG2 
1.00-fold 
(p = 0.86) 
- 
ABCG2 
2.46-fold 
(p < 0.01) 
2.65-fold 
(p < 0.01) 
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Fig. 3-1. Identification of SP and MP cells in canine lymphoma cell lines, UL-1 and Ema. SP 
and MP of UL-1 (A) and Ema (B) were gated. SP disappeared when UL-1 (C) and Ema (D) 
were incubated with reserpine. 
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Fig. 3-2. The comparison of cell-cycle distribution between SP and MP in UL-1 (A) and Ema 
(B). In both of two cell lines, the rates of cells that were in G0/G1 phase were significantly 
larger in SP than MP (p < 0.01). 
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Fig. 3-3. The comparison of quantities of proteins involved in Smad (A) and MAPK/ERK 
pathway (B) between SP and MP of Ema. In Smad pathway, the quantities of phospho-Smad2, 
Smad4 and Smad2 were not different between SP and MP. Smad3 was not detected in Ema. As 
to MAPK/ERK pathway, the quantity of phospho-p44 (ERK1) was found to be larger in SP than 
MP. Western blotting analysis was carried out in triplicate. 
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Fig. 3-4. The confirmation of activation of MAPK/ERK pathway with PMA and its inhibition 
with U0126. The quantity of phosho-p44 (ERK1) was markedly increased by incubation with 
PMA, and this increase was inhibited with U0126 in both of UL-1 and Ema. Western blotting 
analysis was carried out in triplicate. 
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Fig. 3-5. The fold-change of relative quantities of ABCB1 (A) and LRP (B) genes in UL-1 and 
Ema by PMA stimulation and its inhibition with U0126. In both of two cell lines, the relative 
quantities of ABCB1 and LRP genes mRNA were significantly increased by incubation with 
PMA compared with non-treated cells. In addition, when UL-1 and Ema were incubated with 
PMA and U0126, the relative quantities of ABCB1 and LRP genes mRNA were significantly 
decreased compared with those when incubated with PMA alone. *p < 0.01 and †p = 0.02. 
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Fig. 3-6. Changes of the rates of SP in UL-1 and Ema after treatment with PMA and 
PMA+U0126. SP and MP were gated in each scattergram. The rates of SP were significantly 
increased through PMA stimulation in both of UL-1 (B) and Ema (E) compared with 
non-treated UL-1 (A) and Ema (D), respectively. When the cells were pretreated with a 
MAPK/ERK pathway inhibitor, U0126, the increase in rates of SP was significantly inhibited in 
Ema (F), but not in UL-1 (C). Changes of the percentages of SP in three independent assays 
were shown in (G). *p < 0.01.
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Chapter 4 
 
Antitumor effect and modulation of ABCB1 gene 
expression through intracellular signalings by 
perifosine in canine lymphoid tumor cell lines  
108 
 
 
Abstract 
 
Acquisition of multidrug resistance (MDR) is a common cause of failure during 
chemotherapy for dogs with lymphoma. The overexpression of P-glycoprotein (P-gp), 
coded by ABCB1 gene, is known to be associated with MDR. Perifosine, an Akt 
inhibitor, was recently reported to downregulate the expression of P-gp in human 
medicine. However, antitumor effect or modulation of the expression of drug efflux 
pumps by perifosine has not been examined in canine tumor cells. The purpose of the 
present study was to examine the antitumor effect and the modulation of the expression 
of ABCB1 and LRP genes following perifosine treatment in canine lymphoid tumor cell 
lines. In the study in this chapter, 4 different canine lymphoid tumor cell lines, GL-1, 
CLBL-1, UL-1 and Ema were used: the former 2 cell lines were negative for P-gp and 
the latter 2 were positive for P-gp. GL-1 and UL-1 were sensitive to perifosine whereas 
CLBL-1 and Ema were resistant. The amount of ABCB1 mRNA significantly decreased 
after treatment with perifosine through activation of c-jun NH2-terminal kinase (JNK) 
pathway in UL-1, but such an effect was not observed in Ema. The amount of LRP 
mRNA did not change after perifosine treatment in either UL-1 or Ema. In UL-1, the 
efflux of rhodamine 123 dye and the IC50 value for vincristine were reduced by 
perifosine, but such effects were not observed in Ema. In conclusion, perifosine 
produced an antitumor effect, downregulated ABCB1 gene expression, and increased the 
sensitivity for vincristine in a certain type of canine lymphoid tumor cells. 
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Introduction 
 
Lymphoma is the most common hematologic neoplasm in dogs (Dobson et al., 
2001). In most cases, chemotherapy for lymphoma is initially effective; however,  
lymphoma cells acquire multidrug resistance (MDR) phenotype during or after 
chemotherapy, and the treatment tends to fail (Marconato, 2011). Therefore, it is 
important to elucidate the mechanisms that confer MDR phenotype to tumor cells and to 
establish an effective treatment for tumor cells with MDR. 
Various molecules have been shown to induce MDR phenotype in human 
(O'Connor, 2007) and veterinary medicine (Bergman, 2003). Acquisition of MDR 
phenotype is thought to be multifactorial, and the overexpression of efflux pumps such 
as ATP-binding cassette (ABC) transporter family is one of the important MDR factors 
(Bergman, 2003). Among ABC transporters, the efflux pumps coded by ABCB1, ABCC1 
and ABCG2 genes are known to be representative ones associated with the acquisition 
of MDR (Modok et al., 2006). In addition to these ABC transporters, the overexpression 
of lung resistance-related protein (LRP) has also been reported to be associated with 
acquisition of MDR (Gromicho et al., 2011). The overexpression of such transporters 
reduces the intracellular concentration of chemotherapeutic agents. In veterinary 
medicine, the expression of P-glycoprotein, coded by ABCB1 gene, has been reported to 
associate with the MDR phenotype in dogs (Bergman et al., 1996; Lee et al., 1996; 
Moore et al., 1995). However, the mechanisms that induce P-gp overexpression are not 
fully understood, and a successful treatment has not yet been established to overcome 
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the MDR phenotype acquired as a result of P-gp overexpression. 
Perifosine is an anticancer drug that inhibits phosphoinositide 3-kinase (PI3K)/Akt 
pathway, and it is under clinical trial as a treatment for human patients with colorectal 
cancer and multiple myeloma (Srivastava and Cho, 2013). It was reported that 
perifosine inhibited the activation of mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) pathway and activated c-jun 
NH2-terminal kinase (JNK) pathway. In addition, perifosine downregulated the 
expression of P-gp through activation of JNK pathway (Chiarini et al., 2008).  
In veterinary medicine, I revealed that ABCB1 and LRP genes were upregulated by 
MAPK/ERK pathway in canine lymphoma cell lines in chapter 3. However, there has 
been no report on the antitumor effect or the effect on modulation of the expression of 
drug efflux pumps of perifosine in canine tumor cells. 
The purpose of the study in this chapter was to examine the antitumor effect and 
change in the expressions of ABCB1 and LRP genes by the treatment with perifosine in 
canine lymphoid tumor cell lines. 
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Materials and methods 
 
Cell lines 
In the present study, 4 canine lymphoid tumor cell lines were used: GL-1, a canine 
B-cell leukemia cell line (Nakaichi et al., 1996); CLBL-1, a canine B-cell lymphoma 
cell line (Rutgen et al., 2010); UL-1, a canine T-cell lymphoma cell line (Yamazaki et 
al., 2008); and Ema, a canine T-cell lymphoma cell line (Hiraoka et al., 2009). GL-1 
and CLBL-1 do not express ABCB1 gene and P-gp, whereas UL-1 and Ema express 
them as shown in chapter 2-1. All the cell lines were grown in RPMI 1640 
supplemented with 10% fetal calf serum and cultured at 37 °C in a humidified 
atmosphere of 5% CO2. 
 
Drug sensitivity assay 
The 50% inhibitory concentration (IC50) values for perifosine were determined in 
the 4 cell lines. The cells (2 × 10
5
 cell/mL) were cultured in a 96-well plate in media 
containing various concentrations (0.1 – 100 μM) of perifosine (Selleck) for 48 h. 
After cultivation, the viability of the cells was measured using Cell Counting Kit-8 
(Dojindo) according to the manufacturer’s instructions. Absorbance was measured 
using a Model 680 Microplate Reader (Bio-Rad Laboratories), and IC50 values were 
determined. The induction of apoptosis after cultivation with 20 μM of perifosine for 
24 h was also detected using ApoAlert Annexin V-FITC Apoptosis Kit (TaKaRa Bio) 
and FACSCalibur (Becton Dickinson) according to the manufacturer’s instructions. In 
addition, IC50 values for vincristine (Nippon Kayaku) following simultaneous 
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incubation of cells with perifosine were examined in UL-1 and Ema. Cell viabilities 
were measured in cells after simultaneous treatment with 5 μM (in UL-1) or 20 μM (in 
Ema) of perifosine and various concentrations of vincristine (1 - 500 ng/ml) for 48 h. 
The cell viabilities relative to cells treated with perifosine alone were measured as 
described above. To examine the IC50 values for vincristine in UL-1 and Ema without 
treatment with perifosine, cells were incubated with various concentrations of 
vincristine (1 - 500 ng/ml) for 48 h, and the cell viabilities were measured as described 
above. 
 
Western blotting for PI3K/Akt, MAPK/ERK and JNK pathways 
Western blotting was used to examine the activation statuses of PI3K/Akt, 
MAPK/ERK and JNK pathways in cell lines after treatment with 20 μM perifosine as in 
chapter 3. In brief, whole cell lysates were extracted from each cell line using RIPA 
buffer (Cell Signaling Technology), and equal amounts of total protein were separated 
by SDS-PAGE. After blotting on a PVDF membrane, 5% skimmed milk/tris-buffered 
saline with Tween20 was used to block unspecific binding before the membrane was 
incubated with primary antibodies against phospho-Akt (Ser473), phospho-Akt 
(Thr308), Akt (pan), phospho-ERK1/2, ERK1/2, phospho-SAPK/JNK, SAPK/JNK, 
phospho-c-jun, c-jun, and β-actin (Cell Signaling Technology) overnight at 4 C. After 
incubation with the secondary antibody of horseradish peroxidase-labeled anti-rabbit 
IgG (1:3000; Bio-rad Laboratories) for 1 h at room temperature, positive 
immunoreactivity was detected using Luminata Forte Western HRP Substrate 
(Millipore) and visualized using ChemiDoc XRS Plus (Bio-rad Laboratories). 
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Quantification of the amount of ABCB1 and LRP mRNA 
Changes in the expression levels of ABCB1 and LRP genes after treatment with 20 
μM perifosine for 12 h were examined in UL-1 and Ema using real-time reverse 
transcriptase (RT)-polymerase chain reaction (PCR) as described in chapter 1 using the 
same primer pair used in the study of chapter 1. To normalize the amount of the cDNA 
samples, TATA box binding protein (TBP) was selected as an internal reference based 
on the study in chapter 1. Real-time RT-PCR was performed in triplicate. 
 
Inhibition of JNK or PI3K/Akt pathway 
To determine the association between ABCB1 and LRP gene expression and 
signaling pathway activation in UL-1 and Ema cell lines, SP600125 (Wako) and 
LY294002 (Cell Signaling Technology) were used to inhibit the JNK and PI3K/Akt 
pathways respectively. For inhibition of JNK pathway, cells were treated with 50 μM 
SP600125 for 40 min before incubation with 20 μM perifosine for 8 h or 12 h for 
extraction of total RNA or total protein, respectively. The amounts of ABCB1 and LRP 
mRNAs and the amounts of phospho-SAPK/JNK, SAPK/JNK, phospho-c-jun and 
c-jun were compared among non-treated cells, cells treated with perifosine alone, and 
cells treated with both perifosine and SP600125 using real-time RT-PCR and Western 
blotting, as described above. For inhibition of PI3K/Akt pathway, cells were treated 
with 20 μM LY294002 for 3 h or 12 h for extraction of total RNA or total protein, 
respectively. The amounts of ABCB1 and LRP mRNAs and the amounts of 
phospho-Akt (Ser473), phospho-Akt (Thr308) and Akt were compared between 
non-treated cells and cells treated with LY294002 using real-time RT-PCR and Western 
blotting as described above. 
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Rhodamine 123 (Rh) efflux test 
One million UL-1 or Ema cells, with or without pretreatment with 20 μM perifosine 
for 12 h, were incubated with 200 ng/mL of Rh (Sigma-Aldrich) in RPMI 1640 
medium at 37 °C for 20 min. After washing in PBS, the cells were incubated in Rh-free 
medium at 37 °C for 60 min, either with or without 2 μM of cyclosporine (Cs). 
Following incubation, the cells were washed with PBS, and subjected to flow 
cytometric analysis using FACSCalibur (Becton Dickinson). The cells that had not 
been exposed to Rh were used as negative controls, and the Rh efflux index (REI) was 
calculated as (mean fluorescence intensities of the sample incubated with Rh and Cs - 
those of the negative control) / (those of the sample incubated with Rh - those of the 
negative control). The Rh efflux test was performed 5 times. 
 
Statistical analysis 
The nonparametric Mann-Whitney U test was used to compare the relative mRNA 
expression level of ABCB1 and LRP, and REI. The repeated-measures two-way 
ANOVA and Bonferroni post tests were used to compare the cell viabilities after 
incubation with vincristine between cells with and without treatment of perifosine. All 
statistical tests were 2-sided and performed using Prism 5 (GraphPad). For all tests, P 
< 0.05 was used as the level of significance. 
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Results 
 
Cytotoxic effect and modulation of intracellular signaling by perifosine 
The IC50 values for perifosine in GL-1, CLBL-1, UL-1 and Ema were 9.91, 33.0, 
7.01 and 58.7 μM, respectively (Fig. 4-1A). After cultivation with 20 μM of perifosine 
for 24 h, large increase of Annexin-V positive cells was observed in GL-1 and UL-1 
(Fig. 4-1B). Western blotting detected increased amounts of phospho-SAPK/JNK, 
phospho-c-jun, and c-jun following treatment with perifosine in GL-1 and UL-1, 
although these effects were not observed in CLBL-1 and Ema (Fig. 4-2). As for 
MAPK/ERK pathway, a decrease in the amount of phospho-ERK1/2 was observed by 
treatment with perifosine in GL-1, UL-1, and Ema, but this effect was not observed in 
CLBL-1. In addition, decreases in the amounts of phospho-Akt (Ser473) and 
phospho-Akt (Thr308) were observed in GL-1 and UL-1; however, these effects were 
not observed in CLBL-1 and Ema. 
 
Changes in quantities of ABCB1and LRP mRNAs by perifosine 
Treatment with perifosine significantly decreased the amounts of ABCB1 
(0.538-fold) and LRP (0.823-fold) mRNAs in UL-1 (Fig. 4-3A and B); however, the 
extent of the decrease of LRP gene expression in this cell line was within the intra-assay 
error (≥ 0.81-fold in difference). In contrast, the amounts of both ABCB1 and LRP 
mRNAs did not significantly change after treatment with perifosine in Ema (1.03-fold 
and 1.09-fold, respectively; Fig. 4-3C and D).  
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Effects of inhibition of JNK or PI3K/AKT pathway  
In UL-1, the increase of the amounts of phospho-SAPK/JNK, phospho-c-jun, and 
c-jun that was previously observed following treatment with perifosine was inhibited by 
treatment with SP600125 prior to the treatment with perifosine (Fig. 4-4A). In addition, 
the amount of ABCB1 mRNA was significantly increased when cells were incubated 
with both perifosine and SP600125 (0.698-fold) compared with incubation with 
perifosine alone (Fig. 4-4B). However, the amounts of LRP mRNA were not 
significantly different between the cells treated with both perifosine and SP600125 
(0.873-fold) and those treated with perifosine alone (Fig. 4-4C). 
When the inhibition of PI3K/Akt pathway was examined using LY294002, 
decreased amounts of phospho-Akt (Ser473) and phospho-Akt (Thr308) were observed 
in both UL-1 and Ema (Fig. 4-5A). However, the amounts of ABCB1 or LRP mRNAs 
were not significantly different between the cells treated with LY294002 and control 
cells in both UL-1 and Ema (Fig. 4-5B-E). The fold changes in the amounts of ABCB1 
and LRP mRNAs were 1.25- and 1.17-fold in UL-1 and 1.10- and 1.31-fold in Ema, 
respectively. 
 
Changes in efflux function by treatment with perifosine 
To examine the changes in efflux function by treatment with perifosine, Rh efflux 
test was performed. Although the intracellular fluorescence intensities of Rh in cells 
incubated with Rh and Cs were not different between control cells (Fig. 4-6A) and cells 
treated with perifosine (Fig. 4-6B), fluorescence intensities in cells incubated with Rh 
alone was increased in cells treated with perifosine compared with control cells in UL-1. 
However, such a difference was not observed in Ema (Fig. 4-6C and D). The REI value 
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was significantly decreased by treatment with perifosine (4.65) compared with control 
cells (7.29) in UL-1 (Fig. 4-6E), although the REI values were not significantly different 
between control cells (9.73) and cells treated with perifosine (8.36) in Ema (Fig. 4-6F).  
 
Changes in sensitivity for vincristine by treatment with perifosine 
Cell viabilities were examined after treatment of vincristine with or without 
simultaneous perifosine exposure in order to determine whether perifosine affected the 
sensitivity of cells to vincristine. As shown in Fig. 4-7A, in UL-1, the cell viabilities 
when treated with 20 or 30 ng/ml of vincristine were significantly lower in cells 
exposed to perifosine than in cells not exposed to perifosine. The IC50 values for 
vincristine were 15.6 or 29.6 ng/ml in cells with or without treatment with perifosine, 
respectively. In Ema, there was no significant difference in cell viabilities at any 
concentration of vincristine (Fig. 4-7B) between control cells and cells treated with 
perifosine. The IC50 values for vincristine were 77.8 or 81.9 ng/ml in cells with or 
without treatment with perifosine, respectively. 
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Discussion 
 
The present study revealed that perifosine produced an antitumor effect by inducing 
apoptosis and modulated the expression of ABCB1 gene in a certain type of canine 
lymphoid tumor cells. 
IC50 values for perifosine in GL-1, CLBL-1, UL-1 and Ema were revealed to be 
9.91, 33.0, 7.01 and 58.7 μM, respectively. In clinical trials in human medicine, the 
trough levels of perifosine obtained on dosage of 200 mg/day were reported as 2.6 - 8.2 
μg/ml (5.6 – 17.8 μM) (Crul et al., 2002). Considering these data, it might be 
conceivable that 2 of the 4 cell lines used in the present study were sensitive to 
perifosine. 
The results obtained in this study showed that the treatment with perifosine 
inhibited PI3K/Akt and MAPK/ERK pathways, and activated JNK pathway. These 
results were in agreement with the results obtained in a previous study (Chiarini et al., 
2008). In addition, it was revealed in the present study that the modulation of these 
intracellular signaling by perifosine differed among cell lines. All 3 pathways were 
modulated in GL-1 and UL-1, which were sensitive to perifosine, but in the 
perifosine-resistant cell lines CLBL-1 and Ema, none of these pathways and only 
MAPK/ERK pathway was modulated, respectively. Perifosine was reported to exert an 
antitumor effect mainly owing to its ability to the inhibit PI3K/Akt pathway in human 
medicine (Schmidt-Hieber et al., 2012). Considering these observations in human 
medicine and the results of the present study, it was suggested that it might determine 
the sensitivity for perifosine whether inhibition of PI3K/Akt pathway occur or not in 
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tumor cells. 
The ability of perifosine to modulate the expression of ABCB1 and LRP genes as 
well as the function of efflux pumps was examined in UL-1 and Ema, cell liens 
previously identified as being positive for the ABCB1 gene and P-gp in chapter 2-1. The 
amount of ABCB1 mRNA and the REI value significantly decreased by treatment with 
perifosine in UL-1. In addition, the downregulation of ABCB1 gene expression by 
perifosine was significantly inhibited by SP600125, a JNK inhibitor, although treatment 
with LY294002, a PI3K inhibitor, had no effect on ABCB1 mRNA levels. These 
observations suggested that perifosine downregulated ABCB1 gene expression at least 
in part through the activation of JNK pathway, and inhibition of PI3K/Akt pathway 
might not be involved in the downregulation of the expression of this gene. The 
downregulation of the expression of P-gp through the activation of JNK pathway by 
perifosine was also reported in human medicine (Chiarini et al., 2008). The study in 
chapter 3 showed that MAPK/ERK pathway upregulated the expression of ABCB1 and 
LRP genes in UL-1 and Ema. However, treatment with perifosine did not significantly 
alter the amounts of ABCB1 or LRP mRNAs in Ema, despite an inhibition of 
MAPK/ERK pathway by perifosine being observed. Considering these results, the 
inhibition of MAPK/ERK pathway might be insufficient whereas the activation of JNK 
pathway might be important for the downregulation of the ABCB1 gene by perifosine. 
The IC50 value for vincristine decreased by treatment with perifosine (15.6 ng/ml) 
compared with non-treated cells (29.6 ng/ml) in UL-1, although IC50 values in Ema did 
not change, whether perifosine was added or not (77.8 or 81.9 ng/ml, respectively). 
There has been no study on the detailed pharmacokinetics of vincristine in dogs, but the 
Cmax of vincristine was reported to be 21.9 and 28.6 ng/mL, respectively, in 2 human 
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patients when administrated at a dosage of 0.05 mg/kg (Skolnik et al., 2006). Combined 
with the dosage of 0.7 mg/m
2
 in representative chemotherapeutic protocols for canine 
lymphoma patients (Garrett et al., 2002; Keller et al., 1993; Moore et al., 2001), UL-1 
and Ema could be assumed to be resistant to vincristine, and UL-1 might become 
sensitive to vincristine by treatment with perifosine considering the change in IC50 
values for vincristine when incubated with perifosine. In the study in chapter 2-1, 
treatment with cyclosporine (Cs), an ABC-transporter inhibitor, increased the sensitivity 
for vincristine in UL-1 and Ema, and it was suggested that some transporters might be 
associated with vincristine resistance that is seen in these cell lines. On the basis of 
these observations, the use of perifosine might increase the sensitivity of anticancer 
drugs that was substrate for P-gp through downregulation of ABCB1 gene expression in 
a certain type of canine lymphoid tumor cells. 
In conclusion, perifosine downregulated ABCB1 gene expression through activation 
of JNK pathway and increased the sensitivity for vincristine in addition to exerting an 
antitumor effect in a certain type of canine lymphoid tumor cells. Combination 
chemotherapy of perifosine and anticancer drugs that is substrate for P-gp may represent 
an effective treatment for certain types of canine lymphoid tumor cells.  
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Fig. 4-2. The comparisons of quantities of proteins involved in JNK, MAPK/ERK and PI3K/Akt 
pathways between cells with or without treatment with perifosine. All of the three pathways 
were modulated in GL-1 and UL-1 by perifosine, but none of these pathways and only 
MAPK/ERK pathway was modulated in CLBL-1 and Ema, respectively. 
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Fig. 4-3. 
The fold-changes of relative quantities of ABCB1 and LRP genes in UL-1 (a and b, respectively) 
and Ema (c and d, respectively) by treatment with perifosine. In UL-1, the treatment with 
perifosine significantly decreased the amounts of ABCB1 and LRP mRNAs, although the extent 
of the decrease of LRP gene expression was within the intra-assay error. However, those of Ema 
did not significantly change after treatment with perifosine. *p < 0.05. 
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Fig. 4-4. Analysis on the activation of JNK pathway by perifosine and its inhibition by 
SP600125 in UL-1 (a). The quantities of phosho-SAPK/JNK, phospho-c-jun and c-jun increased 
by incubation with perifosine, and this increase was inhibited by SP600125. The fold-changes 
of relative quantities of ABCB1 (b) and LRP (c) genes in UL-1 by the treatments with perifosine 
alone and perifosine plus SP600125. Decrease of the amount of ABCB1 mRNA by the treatment 
with perifosine was restored by the treatment with SP600125, but the amounts of LRP mRNA 
were not significantly different between cells treated with both perifosine and SP600125 and 
cells treated with perifosine alone. *vs. control; p < 0.05, and †vs. cells treated with perifosine; 
p < 0.05. 
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Fig. 4-5. Analysis on the inhibition of PI3K/Akt pathway with LY294002 in UL-1 and Ema (a). 
The quantities of phosho-Akt (Ser473) and phospho-Akt (Thr308) decreased by incubation with 
LY294002. The fold-changes of relative quantities of ABCB1 and LRP genes in UL-1 (b and c, 
respectively) and Ema (d and e, respectively) by treatment with LY294002. The amount of 
ABCB1 or LRP mRNA did not significantly change by treatment with LY294002 in both of 
UL-1 and Ema. 
126 
 
 
Fig. 4-6. The results of rhodamine 123 (Rh) efflux test in control cells and cells treated with 
perifosine in UL-1 (a and b, respectively) and Ema (c and d, respectively).  Although the 
intracellular fluorescence intensities of Rh in the cells incubated with Rh and cyclosporine (Cs) 
were not different between the control cells (a) and those treated with perifosine (b), that of cells 
incubated with Rh alone was increased in cells treated with perifosine compared with control 
cells in UL-1. However, such a difference was not observed in Ema (c and d). The REI value 
significantly decreased when treated with perifosine compared with control cells in UL-1 (e), 
but those of Ema did not significantly change by treatment with perifosine (f). *p < 0.05. 
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Fig. 4-7. The dose-response curves of the cytotoxic effect of vincrisine in UL-1 (a), and Ema (b) 
with or without treatment with perifosine. The cell viability data were plotted against the log of 
vincristine concentrations. The data represent the mean ± SD of triplicate cultures. *p < 0.01. 
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Chapter 5 
 
Comprehensive comparison of gene expression 
profiles between drug-sensitive and drug-resistant 
phases in canine lymphoma patients  
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Abstract 
 
Multidrug resistance (MDR) is one of the major obstacles during the chemotherapy 
in canine lymphoma patients. Although there have been various molecules that were 
shown to be associated with acquisition of MDR phenotype in human and canine tumor 
cells, the mechanisms that confer MDR phenotype to tumor cells have not been well 
understood. Therefore, new MDR factor(s) should be identified to overcome the MDR 
phenotype of canine lymphoma cells. In the present study, a comprehensive analysis of 
changes in gene expression profiles of lymphoma cells was conducted by microarray 
analysis using tumor cell samples at drug-sensitive and drug-resistant phases in 4 dogs. 
By gene ontology analysis and gene set enrichment assay, it was revealed that 
downregulation of genes that were associated with immunological reaction such as 
chemotaxis and inflammation was found to be a common change in the drug-resistant 
phase of the 4 dogs. Further studies are needed to examine the association of such 
change of the gene expression profiles with the acquisition of MDR phenotype in canine 
lymphoma cells. 
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Introduction 
 
Multidrug resistance (MDR) is one of the major obstacles during the chemotherapy 
in the patients with various cancers including lymphoma. A lot of molecules that 
contribute to the development of MDR have been reported in human neoplastic cells 
(Gimenez-Bonafe et al., 2009; Harris and Hochhauser, 1992). Several mechanisms 
including overexpression of drug transporter (O'Connor, 2007),  aberrations in 
molecules associated with apoptosis such as p53 and bcl-2 gene (Kupryjanczyk et al., 
2003), increased detoxification of anticancer drug (Moscow and Dixon, 1993) and 
enhancement of DNA repair function (Gerson, 2004) have been shown to be associated 
with the acquisition of MDR in tumor cells of human origin. However, the expression 
levels of genes encoding these molecules were not significantly different between dogs 
with chemotherapy-sensitive and -resistant lymphoma, although overexpression of 
ABCB1 gene was observed in 3 of 10 dogs with chemotherapy-resistant lymphoma in 
chapter 1. Therefore, it was indicated that novel MDR factor(s) should be identified to 
elucidate the mechanisms of MDR acquisition in canine lymphoma cells. 
In human medicine, comprehensive analysis of gene expression profile has been 
conducted to identify significant MDR factors in tumor cells. As to the lymphoid tumor, 
comprehensive comparison of gene expression profile of diffuse large B-cell lymphoma 
(DLBCL) cells between patients that achieved continuous complete remission by 
treatment and patients that developed progressive disease during treatment was 
conducted using microarray analysis in one study (Linderoth et al., 2008). In their study, 
the enhanced immunological reaction in the tumor microenvironment of tissues was 
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demonstrated in the tumor cells obtained from patients that achieved continuous 
complete remission. However, there has been no study that analyzed novel MDR factors 
by comprehensively analyzing gene expression profiles in tumor cells obtained from 
patients in dogs. 
The purpose of the present study was to investigate the novel common MDR 
factor(s) in canine lymphoma by comprehensive analysis of changes in gene expression 
profile using tumor cell samples obtained at drug-sensitive and drug-resistant phases of 
the same patients.
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Materials and Methods 
 
Patient samples 
Four dogs that were referred to the Veterinary Medical Center of the University of 
Tokyo and diagnosed as multicentric high-grade lymphoma according to cytological 
examinations of enlarged lymph nodes based on updated Kiel classification 
(Fournel-Fleury et al., 1997) were included in the present study (Table 5-1). Lymphoma 
cell samples from all 4 dogs were shown to be clonally expanded B-lymphoid cells by 
PCR amplification test for the antigen receptor gene rearrangements as described 
previously (Burnett et al., 2003). 
A cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine, plus 
prednisolone (CHOP)-based chemotherapy, 6-month modified version of the University 
of Wisconsin (UW) - Madison chemotherapy protocol (UW-25) (Garrett et al., 2002), 
was used as a standard multidrug combination chemotherapy protocol. Veterinarians 
measured the size of the lymph nodes with calipers at each admission, and response to 
treatment was evaluated based on the Response Evaluation Criteria in Solid Tumors 
(RECIST) (Eisenhauer et al., 2009). In the evaluation of response to treatment, complete 
response (CR) and partial response (PR) were regarded as indicating 
chemotherapy-sensitive status, and stable disease (SD) and progressive disease (PD) 
were regarded indicating as chemotherapy-resistant status. 
Dogs were regarded as chemotherapy-sensitive if they achieved CR or PR by week 
5 of the UW-25 protocol. Tumor cell samples were collected just prior to the 
chemotherapy at the initial consultation by fine needle aspiration (FNA). Dogs were 
regarded as chemotherapy-resistant if they had underwent a relapse after achieving 
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remission by UW-25 protocol and did not respond to all of the three chemotherapeutic 
agents used for UW-25, cyclophosphamide, doxorubicin, and vincristine. The tumor cell 
samples in the chemotherapy-resistant group were collected after confirming the 
non-responsiveness to these three drugs in conjunction with prednisolone after the 
relapse by FNA. Tumor cell samples at both of chemotherapy-sensitive and -resistant 
phases were collected in each patient, and a total of 8 tumor cell samples were used in 
the present study. 
 
Microarray analysis 
Total RNA was isolated from tumor cell samples that had been stored in RNA later 
(Ambion, Austin, TX, USA) at -20 C using RNeasy Mini Kit (QIAGEN, Hilden, 
Germany) according to the manufacturer’s instruction. The RNA quantity and qualtiy 
were assessed using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA) and RNA integrity numbers were confirmed as above 9.0. The synthesis of cDNA 
and Cy3 labelled cRNA were conducted using Low Input Quick Amp Labeling Kit 
(Agilent Technologies) and One-Color RNA Spike-In Kit (Agilent Technologies). The 
labelled cRNAs were purified using RNeasy Mini Kit (QIAGEN), and fragmented and 
hybridized to Canine oligo DNA microarray ver.2 (4×44K) (Agilent Technologies) 
using Gene Expression Hybridization Kit (Agilent Technologies). After hybridization, 
slide was washed with Gene Expression Wash Buffer Kit (Agilent Technologies), and 
was scanned using High-Resolution Microarray Scanner (Agilent Technologies). All 
image and data analysis were conducted using Feature Extraction software (Agilent 
Technologies). Three probe sets were used for each sample. Spots with low intensity 
were eliminated from the analysis. The data was normalized, filtered and complicated 
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using Gene Spring GX software (Agilent Technologies). Only those genes, which 
showed log2 values greater than 1 (2-fold upregulated in drug-resistant samples) or less 
than -1 (2-fold upregulated in drug-sensitive samples) were included in analysis. The 
comparison of gene expression profiles between the drug-sensitive and drug-resistant 
phases was conducted by principal component analysis (PCA) and gene ontology (GO) 
analysis using Gene Spring GX software (Agilent Technologies) and gene set 
enrichment analysis (GSEA) using GSEA software (Broadinstitute, Cambridge, MA, 
USA). P < 0.05 was defined as significant. 
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Results 
 
At first, PCA analysis using all 24 expression profiles extracted from 8 samples 
were conducted. As a result, it was revealed that the differences of gene expression 
profiles among patients were larger than those between drug-sensitive phase samples 
and drug-resistant phase samples (Figure 5-1). Therefore, the comparisons of expression 
profiles between drug-sensitive phase sample and drug-resistant phase sample of the 
same patient were conducted. In each of the 4 dogs analyzed, 511, 659, 157 and 338 
genes were significantly upregulated in their drug-resistant phase; meanwhile, 1165, 
2754, 1366 and 306 genes were significantly downregulated in their drug-resistant 
phase (Table 5-2). 
In GO analysis, the upregulated genes in drug-resistant phase in dog 1 were 
significantly associated with 16 ontologies, although those in other 3 dogs were not 
associated with any ontology (Table 5-2). The downregulated genes in drug-resistant 
phase were significantly associated with 100, 364, 234 and 8 ontologies in 4 dogs, 
respectively (Table 5-2). Among these ontologies, 70 ontologies and 1 ontology were 
common among 3 dogs, respectively, and 2 ontologies were common among all of the 4 
dogs (Figure 5-2). The 2 ontologies that were common among 4 dogs were 
‘extracellular region’ and ‘extracellular region part’, and a common ontology among 
dog 1, 3 and 4 was ‘binding’. The 70 ontologies that were common among dog 1, 2 and 
3 included ontologies that were associated with cell chemotaxis and cell migration and 
immune response (Table 5-3). 
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In GSEA, the upregulated genes in drug-resistant phase were significantly 
associated with 11, 5, 5 and 9 terms in each of the 4 dogs (Table 5-2 and 5-4), and no 
terms were common among 3 or 4 dogs. The downregulated genes in drug-resistant 
phase were significantly associated with 49, 102, 72 and 23 terms in each of the 4 dogs 
(Table 5-2). Among these terms, 21, 3 and 1 term were common among the 3 dogs, and 
10 terms were common among all of the 4 dogs (Figure 5-3). The terms that were 
common among 4 dogs included “chemokine signaling pathway”, “leukocyte 
transendothelial migration” and “NOD like receptor signaling pathway” (Table 5-5). 
The 21 terms that were common among dog 1, 2 and 3 included terms that were 
associated with immune response such as “cytokine cytokine receptor interaction”, 
“natural killer cell mediated cytotoxicity”, “T-cell receptor signaling pathway” and 
“Toll-like receptor signaling pathway” (Table 5-5). 
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Discussion 
 
It was revealed that downregulation of genes associated with immunological 
reaction including inflammation and chemotaxis was found to be a common change in 
drug-resistance phase of 4 dogs analyzed in the study of this chapter. 
In PCA analysis, it was shown that the differences of gene expression profiles 
among patients were larger than those between drug-sensitive phase samples and 
drug-resistant phase samples. As shown in the study in chapter 1, the expression levels 
of genes that were associated with MDR were variable among patients that acquired 
MDR. These observations indicated that it was needed to detect the changes of gene 
expression profiles during the acquisition of MDR phenotype of lymphoma cells using 
tumor cell samples derived from the same patients. Therefore, the comparisons of gene 
expression profiles between drug-sensitive phase sample and -resistant sample of each 
patient were conducted, and common changes in gene expressions among 4 dogs were 
investigated in the study of this chapter. 
In GO analysis, 70 ontologies that were associated with downregulated genes in 
drug-resistant phase were common among dogs 1, 2 and 3, although only 2 ontologies 
were common among all of the 4 dogs. These findings indicated that the changes in 
gene expression profiles during the acquisition of MDR were more similar among dogs 
1, 2 and 3 than among all of 4 dogs. In dog 4, upregulation of ABC transporters, which 
was already shown to be associated with the acquisition of MDR phenotype, was noted 
in GSEA, although similar result was not observed in dog 1, 2 and 3. It was suggested 
that the upregulation of ABC transporters was one of the causes of the acquisition of 
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MDR in lymphoma cells of dog 4, although similar mechanisms was not associated 
with the acquisition of MDR in other 3 dogs. 
In GSEA, downregulation of genes associated with immunological reaction 
including chemotaxis and inflammation, which was common change among dogs 1, 2 
and 3 in GO analysis, was common change among all of 4 dogs. These results suggested 
that the downregulation of immunological reaction such as chemotaxis and 
inflammation was a common event associated with the acquisition of MDR phenotype 
in all of the 4 dogs analyzed here. In human medicine, it was revealed that a mammary 
adenocarcinoma cell line treated with tamoxifen upregulated the expression of 
macrophage migration inhibitory factor, which is a pro-inflammatory cytokine and key 
modulator of immune responses, in macrophages when the cell line was cocultured with 
macrophages (Burnett et al., 2008). This result suggested that the tumor cells that were 
subjected to anticancer drug had the function to modulate the immunological reaction of 
cells such as macrophages. In addition, I revealed that M2 macrophages had antitumor 
effect against canine lymphoma cells by inducing apoptosis (data not shown). Based on 
these observations, it is reasonable to hypothesize that the loss of immunological 
reaction such as chemotaxis and inflammation in tumor cells might be associated with 
the loss of antitumor effect induced by chemotherapeutic agents. 
Further studies are needed to validate the decrease of molecules that were 
associated with chemotaxis and inflammation in protein level in MDR lymphoma 
tissues. It is also needed to examine the cell types that express these molecules in 
lymphoma tissues by using immunohistochemistry. However, it was reported that FNA 
samples of canine multicentric lymphoma contained few cells other than tumor cells 
(Sato et al., 2012), and it might be suggested that the results in microarray analysis in 
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the present study might reflect the changes in gene expression profiles of lymphoma 
cells. 
In conclusion, the study of this chapter revealed that the downregulation of genes 
that were associated with immunological reaction such as chemotaxis and inflammation 
might be MDR factor in canine lymphoma. Further studies are needed to examine the 
association of this change and the acquisition of MDR phenotype in lymphoma cells. 
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Table 5-1.  
Signalments of 4 dogs with lymphoma that underwent microarray analysis for the tumor cells. 
Dog 
Age 
(years old) 
Sex Breed 
BW 
(kg) 
1 9.9 Male Shih Tzu 6.2 
2 8.8 Male Doberman 25.7 
3 2.8 Male (castrated) French bulldog 10.3 
4 4.5 Female (spayed) French bulldog 12.8 
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Table 5-3.  
The 70 ontologies that were commonly associated with downregulated genes in drug-resistant 
phase samples of dog 1, 2 and 3 in gene ontology analysis 
Cell chemotaxis and cell migration cell chemotaxis 
 
cell migration 
 
cellular component movement 
 
chemokine activity 
 
chemotaxis 
 
locomotion 
 
positive regulation of cell migration 
 
positive regulation of cell motility 
 
positive regulation of cellular component movement 
 
positive regulation of locomotion 
 
regulation of cell migration 
 
regulation of cell motility 
 
regulation of cellular component movement 
 
regulation of chemotaxis 
 
regulation of localization 
 
regulation of locomotion 
 
taxis 
  
Response to stimulus cellular response to chemical stimulus 
 
positive regulation of response to external stimulus 
 
positive regulation of response to stimulus 
 
regulation of response to external stimulus 
 
regulation of response to stimulus 
 
response to chemical stimulus 
 
response to external stimulus 
 
response to organic substance 
 
response to oxygen-containing compound 
 
response to stimulus 
  
Binding calcium ion binding 
 
carbohydrate derivative binding 
 
glycosaminoglycan binding 
 
growth factor binding 
 
heparin binding 
 
receptor binding 
 
sulfur compound binding 
  
Antomical structure development anatomical structure development 
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cardiovascular system development 
 
circulatory system development 
 
developmental process 
 
multicellular organismal development 
 
organ development 
 
system development 
 
tissue development 
  
Cellular component cell surface 
 
external side of plasma membrane 
 
extracellular membrane-bounded organelle 
 
extracellular organelle 
 
extracellular space 
 
extracellular vesicular exosome 
 
plasma membrane part 
  
Immune response immune response 
 
immune system process 
 
inflammatory response 
 
positive regulation of immune system process 
 
positive regulation of inflammatory response 
 
regulation of immune system process 
  
Defense response defense response 
 
response to stress 
 
response to wounding 
  
Regulaltion of cell death regulation of apoptotic process 
 
regulation of cell death 
 
regulation of programmed cell death 
  
Others biological regulation 
 
extracellular matrix 
 
positive regulation of biological process 
 
positive regulation of transport 
 
regulation of biological process 
 
regulation of biological quality 
 
regulation of cell adhesion 
 
regulation of multicellular organismal process 
  single-multicellular organism process 
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Table 5-4.  
The terms that were associated with upregulated genes in drug-resistant phase samples of each 
patient. 
Terms Dog 
Base excision repair 1 
Cell cycle 1 
Citrate cycle TCA cycle 1 
DNA replication 1 
Homologous recombination 1 
Mismatch repair 1 
Neurotrophon signaling pathway 1 
Nucleotide excision repair 1 
Parkinsons disease 1 
Proteasome 1 
RIG I like receptor signaling pathway 1 
Base excision repair 2 
Propanoate metabolism 2 
Spliceosome 2 
Steroid biosynthesis 2 
Valine leucine and isoleucine degradation 2 
Basal transcription factors 3 
Butanoate metabolism 3 
Selenoamino acid metabolism 3 
Steroid biosynthesis 3 
Tyrosine metabolism 3 
ABC transporters 4 
Alanine aspartate and glutamate metabolism 4 
Ether lipid metabolism 4 
Glycerophospholipid metabolism 4 
Glycine serine and threonine metabolism 4 
Glycosaminoglycan biosynthesis chondroitin sulfate 4 
Hematopoietic cell lineage 4 
Porphyrin and chlorophyll metabolism 4 
RNA polymerase 4 
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Table 5-5.  
The terms that were commonly associated with downregulated genes in drug-resistant phase 
samples of 3 or 4 dogs in gene set enrichment assay. 
Common terms among 4 dogs Adherens junction 
 
Arrhythmogenic right ventricular cardiomyopathy arvc 
 
Chemokine signaling pathway 
 
Cytosolic DNA sensing pathway 
 
Focal adhesion 
 
Leishmania infection 
 
Leukocyte transendothelial migration 
 
NOD like receptor signaling pathway 
 
Pathways in cancer 
 
Systemic lupus erythematosus 
  
Common terms among dog 1, 2 and 3 Arginine and proline metabolism 
 
Axon guidance 
 
Bladder cancer 
 
Calcium signaling pathway 
 
Colorectal cancer 
 
Complement and coagulation cascades 
 
Cytokine cytokine receptor interaction 
 
Dilated cardiomyopathy 
 
Drug metabolism other enzymes 
 
ECM receptor interaction 
 
Epithelial cell signaling in helicobacter pylori infection 
 
Gap junction 
 
Hematopoietic cell lineage 
 
Hypertrophic cardiomyopathy HCM 
 
Melanoma 
 
Natural killer cell mediated cytotoxicity 
 
Prion diseases 
 
Regulation of actin cytoskeleton 
 
Small cell lung cancer 
 
T cell receptor signaling pathway 
 
Toll like receptor signaling pathway 
  
Common terms among dog 2, 3 and 4 Fatty acid metabolism 
 
TGFβ signaling pathway 
 
Tight junction 
  
Common terms among dog 1, 2 and 4 Pancreatic cancer 
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Fig. 5-1. The results of PCA analysis using all 24 expression profiles extracted from 8 samples 
were conducted. It was revealed that the differences of gene expression profiles among patients 
were larger than those between drug-sensitive phase samples and drug-resistant phase samples 
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Fig. 5-2. The numbers of common ontologies that were associated with downregulated genes in 
drug-resistant phase samples among 3 or 4 dogs in gene ontology analysis. Although 70 
ontologies were common among dog 1, 2 and 3, only 2 ontologies were common among all of 
the 4 dogs. 
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Fig. 5-3. The numbers of common terms that were associated with downregulated genes in 
drug-resistant phase samples among 3 or 4 dogs in gene set enrichment assay. The 21 terms 
were common among dog 1, 2 and 3, and 10 terms were common among all of the 4 dogs. 
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Conclusion 
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Acquisition of multidrug resistance (MDR) is one of the major causes of the failure 
in chemotherapy for various tumors including lymphoma. Several mechanisms have 
been proposed as the mechanisms that confer MDR phenotype to tumor cells, and 
various molecules were shown to be associated with MDR phenotype. However, the 
mechanisms of the acquisition of MDR in tumor cells have not been well understood. A 
series of studies in the present thesis were carried out to elucidate the molecular 
mechanisms of the acquisition of MDR phenotype in canine lymphoma. 
In chapter 1, expression levels of 10 genes that were associated with MDR in 
human medicine and mutation of p53 gene were examined in dogs with multicentric 
high-grade lymphoma to explore their association with drug resistance of the tumor 
cells. The expression levels of these genes and frequency of p53 gene mutation were 
compared between drug-sensitive and drug-resistant groups. As a result, no significant 
differences were observed in expression levels of each gene between groups. However, 
3 dogs in the chemotherapy-resistant group showed high expression of ATP-binding 
cassette, sub-family B, member 1 (ABCB1). In addition, no significant difference was 
observed in the frequency of p53 mutation between groups. Therefore, a possible 
association of ABCB1 with resistance to 6-month modified version of the University of 
Wisconsin (UW)-Madison chemotherapy protocol (UW-25) was shown in certain types 
of canine lymphoma patients. 
Next, epigenetic regulation of canine ABCB1 gene was examined in canine 
lymphoid tumor cell lines and primary tumor cells derived from multicentric high-grade 
lymphoma patients to elucidate the mechanisms that induce overexpression of ABCB1 
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gene in chapter 2. In canine lymphoid tumor cell lines, 2 vincristine-sensitive cell lines, 
GL-1 and CLBL-1, expressed low levels of ABCB1 gene possibly through 
hypermethylation of the CpG motif and histone H3 hypoacetylation compared with 2 
vincristine-resistant cell lines, UL-1 and Ema. In addition, treatments with a DNA 
methyltransferase inhibitor (5-aza 2’-deoxycytidine; 5-aza dC) and a histone 
deacetyltransferase inhibitor (trichostatin A; TSA) significantly increased the expression 
of ABCB1 gene in GL-1 and CLBL-1. These results indicated that DNA methylation 
and histone H3 acetylation were associated with the regulation of ABCB1 gene 
expression. However, in primary tumor cells obtained from canine lymphoma patients, 
ABCB1 gene expression was not silenced by DNA methylation before chemotherapy, 
and it was indicated that expression regulation through DNA methylation was not 
associated with the overexpression of ABCB1 gene in MDR lymphoma cells. 
Based on the results in chapter 2, other mechanisms that induced overexpression of 
ABCB1 gene were investigated based on cancer cell concept in chapter 3. In 2 
lymphoma cells, UL-1 and Ema, side population (SP) fraction, which is thought to 
contain cancer stem cells, was observed, and SP was shown to express larger amount of 
ABCB1 and LRP mRNA compared with other cell fraction (major population, MP). In 
addition, SP was found to express larger amount of TGF-β type II receptor mRNA 
compared with MP in microarray analysis, and mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) pathway, which is downstreamt of 
TGF-β signaling, was more activated in SP than MP. Finally, it was revealed that 
MAPK/ERK pathway upregulated the expression of ABCB1 and LRP genes in these 2 
cell lines. From the results of chapter 3, it was indicated that activation of a intracellular 
signaling, MAPK/ERK pathway, was involved in regulation of ABCB1 gene expression.  
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In chapter 4, the decrease of the expression of ABCB1 gene by modulation of 
intracellular signalings including MAPK/ERK pathway was examined based on the 
results in chapter 3. As a result, perifosine, an Akt inhibitor, had antitumor effect in 2 of 
4 canine lymphoid tumor cell lines, GL-1 and UL-1. The amount of ABCB1 mRNA 
significantly decreased after treatment with perifosine through activation of c-jun 
NH2-terminal kinase (JNK) pathway in UL-1. In this cell line, the efflux of rhodamine 
123 dye and the IC50 value for vincristine were reduced by perifosine, but such effects 
were not observed in Ema. In summary, perifosine had an antitumor effect, 
downregulated ABCB1 gene expression, and increased the sensitivity for vincristine in a 
certain type of canine lymphoid tumor cells. 
Finally in chapter 5, novel MDR factor(s) in canine lymphoma were investigated 
by comprehensive analysis of changes in gene expression profiles at acquisition of 
MDR phenotype using microarray analysis. In gene ontology analysis and gene set 
enrichment assay, the downregulation of genes that were associated with immunological 
reaction such as chemotaxis and inflammation was commonly observed among all of 
the 4 dogs examined, and it was suggested that these changes may correspond to the 
new MDR factors in canine lymphoma. 
In this thesis, the overexpression of ABCB1 was focused based on the results in 
chapter 1. Then, the molecular mechanisms that induce overexpression of ABCB1 gene 
was investigated in chapters 2 and 3. Moreover, the reduction of the expression of 
ABCB1 gene and reconstitution of the sensitivity to vincristine by treatment with 
perifosine was shown in certain types of canine lymphoma cells in chapter 4. In these 
chapters, the changes in molecular mechanisms occurring within tumor cells were 
focused to elucidate the mechanisms of the acquisition of MDR phenotype. In addition 
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to these studies, it was suggested that decrease of immunological reaction might be new 
MDR factor in canine lymphoma from the results of chapter 5. In human medicine, it 
has been indicated that changes in interactions of tumor cells with stromal cells in tumor 
tissues had important effects in acquisition of MDR phenotype of tumor cells (Rebucci 
and Michiels, 2013). Based on the results in chapter 5 and previous studies in human 
medicine, the changes in tumor microenvironments might be one of the key 
mechanisms to elucidate and overcome the acquisition of MDR of tumor cells. 
The overexpression of ABC-transporters is one of the most extensively studied 
mechanisms that are associated with MDR phenotype in human (O'Connor, 2007) and 
veterinary medicines (Bergman, 2003). However, it was reported that expression of 
P-gp is not always linked to MDR in vivo and inhibition of the function of P-gp cannot 
always re-establish sensitivity for chemotherapeutic agents (Leonard et al., 2003). In the 
results of chapter 1 in this thesis, larger amount of ABCB1 mRNA was expressed in 3 of 
10 dogs with MDR lymphoma, but not in other 7 dogs. These observations suggested 
that the acquisition of MDR might be multifactorial, and the mechanisms of MDR 
might be different among patients. Therefore, it was needed to identify more new MDR 
mechanisms and to classify the mechanisms that were associated with acquisition of 
MDR mechanisms in each patient by analyzing large number of patients. In addition to 
the results obtained by comprehensive analysis of changes in gene expression profiles in 
chapter 5, it might also help to identify new MDR mechanisms to analyze the changes 
in genomic DNA sequence during acquisition of MDR phenotype by whole sequence 
analysis using next generation sequencing as conducted in human medicine (Tzoneva et 
al., 2013). 
In conclusion, the association of overexpression of ABCB1 gene with MDR in 
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canine lymphoma, the molecular mechanisms that induced overexpression of ABCB1 
gene, and the effect of perifosine to re-establish the sensitivity to substrate of P-gp were 
shown in a series of the studies in this thesis. In addition, it was also suggested that 
decrease of the immunological reaction in lymphoma cells might be new MDR factors. 
I believe that the results obtained in this thesis advanced the research to elucidate the 
molecular mechanisms and will contribute to develop effective therapy for tumor cells 
with MDR phenotype in both humans and dogs. 
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